Podcasts about NIF

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodes Enter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

In the Season 14 premiere, hosts Dan Ivovich and Sundi Myint chat with Isaac Yonemoto, creator of the Zigler library, to explore how Zigler brings Zig's performance and safety to Elixir through Native Implemented Functions (NIFs). Isaac walks through the core design of Zigler and how it auto-generates the Elixir-to-Zig bridge, enforces type safety, and exposes multiple execution modes (normal, dirty, threaded). The conversation covers real-world applications, from SIMD-powered token selection for LLM hardware acceleration to OTP-style fault tolerance in low-level code. Isaac shares his own journey: stepping back from professional software work to launch a biotech startup focused on reducing drug manufacturing costs while continuing to maintain Zigler and even leveraging Elixir for bioinformatics pipelines. Topics discussed in this episode: What is the Zigler library and what does it do? What does it mean to run a "dirty NIF"? Async mode is temporarily removed from Zig (therefore, yielding NIFs is temporarily deprecated in Zigler) Zigler's three execution modes (normal, dirty, and threaded) and how you switch modes with a single config change Isaac's journey from professional software work to launching a biotech startup How Isaac leverages Elixir in bioinformatics pipelines at his startup LLM hardware acceleration using Zigler NIFs and SIMD-powered token picking Fault-tolerant load balancing of NIF workloads via OTP principles Transparent handling and recovery from hardware failures through monitoring Potential future memory-safety features in Zig and their implications The Elixir-based borrow-checker prototype: purpose and design Unit-checking for scientific computations to enforce correctness New OS support in Zigler 0.14: macOS, Windows, and FreeBSD Inline Zig code authoring directly within Elixir modules Isaac's commitment to maintain Zigler through its 1.0 release (...and beyond?) Links mentioned: https://github.com/E-xyza/zigler https://github.com/ziglang/zig https://vidalalabs.com/ Zig Programming Language: https://ziglang.org/ https://obsidian.md/ https://hexdocs.pm/elixir/macros.html https://erlang.org/documentation/doc-4.7.3/doc/extensions/macros.html A Deep Dive Into the Elixir AST: https://dorgan.ar/posts/2021/04/theelixirast/ https://www.erlang.org/doc/system/nif.html https://nodejs.org/en Llama Open-Source LLM: https://www.llama.com/ Mixtral Open-Source LLM: https://mistral.ai/news/mixtral-of-experts https://Fly.io SIMD: https://en.wikipedia.org/wiki/Singleinstruction,multiple_data https://opentrons.com/ CI/CD: https://en.wikipedia.org/wiki/CI/CD https://hexdocs.pm/zigler/Zig.html http://www.x.com/DNAutics https://bsky.app/profile/dnautics.bsky.social

El abogado Sergio Marco ha sido elegido gerente, y como representantes de los diferentes comités, Teresa Vicente, profesora de Filosofía del derecho e impulsora de la ILP, representará a la Comisión de Representantes; Mario Cervera, alcalde de Los Alcázares, representará a la Comisión de Seguimiento, y el profesor de Ecología Miguel Ángel Esteve al Comité Científico.La profesora Teresa Vicente, impulsora de la Ley de personalidad jurídica del Mar Menor, califica este día como de "alfabetización" ecológica de la ciudadanía.Entre los integrantes de los diferentes comités se han dado cita representantes de sectores diversos y que hoy han compartido una posición común, la de "hacer lo que sea necesario" para proteger al Mar Menor.Así lo manifestaban representantes tanto de la agricultura como de defensa del patrimonio de corte ambientalista como son Vicente Carrión, presidente de COAG en la Comarca de Cartagena, y Ramón Pagán, portavoz de la Plataforma social Pacto por el Mar Menor.A partir de hoy, y según exige la Ley de Personalidad Jurídica del Mar Menor, ya se pueden iniciar los trámites para que el pequeño mar pueda obtener su NIF y, por lo tanto, operar con personalidad jurídica ante los tribunales y ante las administraciones.

This is our weekly compilation of science news.00:00 - New Nuclear Fusion Record at NIF! Can laser fusion break even?5:28 - The USA is crumbling at the bottom and sinking10:05 - Gravity might be a force after all15:11 - Black Holes might turn into White Holes, and make up dark matter, physicists say

Em vários países africanos, há sinais de que quando os governos conseguem cobrar impostos, também tendem a melhorar a qualidade da democracia. O economista angolano Francisco Paulo, acaba de terminar o doutoramento no Instituto Universitário de Lisboa com uma tese sobre “Tributação em África e Reformas Fiscais em Angola”, explica-nos que, quando os cidadãos começam a pagar impostos e percebem que estão a financiar os serviços públicos, ganham mais consciência cívica e exigem mais dos seus governantes. RFI: O que é que o motivou a estudar o tema dos impostos e por que escolheu Angola como caso de estudo?Francisco Paulo: O que me levou a estudar os impostos em África… sabe que o continente africano, na verdade, se analisarmos os dados macroeconómicos, é um dos continentes com menor colecta de impostos em comparação com os restantes. Em média, a percentagem dos impostos no PIB em África anda à volta dos 14%, enquanto noutros continentes ronda os 30%, 20%. África cobra menos impostos. E, se compararmos com os níveis de democracia, os países africanos também são, em geral, os que têm os níveis mais baixos de democracia.Por que é que África cobra menos impostos? Existem várias razões. A literatura aponta também alguns aspectos, como o facto de a democracia, em alguns países africanos, ser considerada imposta pelo Ocidente, no sentido de que grande parte da ajuda pública ao desenvolvimento é condicionada pelo respeito pelos direitos humanos e pela implementação da democracia. Quisemos analisar até que ponto a ajuda ao desenvolvimento contribui efectivamente para a democracia em África, e que impacto factores como os impostos podem ter no seu reforço, tendo em conta a teoria do contrato social.Nota-se que, quando a população começa a pagar impostos, desenvolve uma maior consciência cívica, especialmente nos países africanos, porque compreende que os serviços públicos prestados pelo governo não são gratuitos, e que participam nas despesas. Quando isso acontece, há níveis mais elevados de democracia e uma maior responsabilização por parte dos governos.O estudo mostra que há uma relação em forma de "U invertido" entre democracia e carga fiscal. Pode explicar-nos de forma simples o que isto quer dizer?Essa relação em forma de U invertido significa que, numa fase inicial, o aumento da carga fiscal ou seja, a carga fiscal que incide sobre a população e sobre as empresas, e não sobre a exploração de recursos naturais, contribui para o aumento dos índices de democracia. No entanto, esse aumento só ocorre até um certo limiar. No nosso estudo, esse limiar situa-se entre os 26% e os 27% de receitas fiscais em proporção do PIB.Se esse limiar for ultrapassado, um aumento na carga fiscal pode provocar uma diminuição nos índices de democracia. Quando os impostos se tornam demasiado elevados, as pessoas deixam de querer pagá-los. E os governos, por vezes, podem adoptar atitudes autoritárias para forçar o pagamento. Por isso, essa relação é em U invertido: o aumento da carga fiscal promove a democracia até certo ponto, depois disso, pode ter o efeito contrário.É isso que está a acontecer em Angola?Bom, em Angola, podemos notar que uma das melhores coisas que aconteceu nos últimos anos foi a diminuição das receitas fiscais petrolíferas. Com essa redução, o governo foi obrigado a começar a cobrar impostos ao sector não petrolífero.Esses impostos; como o IRT (Imposto sobre o Rendimento do Trabalho) e o IVA, afectam directamente a população, que sente que paga impostos, mas não vê retorno em termos de serviços públicos.A população não tem retorno?Não há retorno, e a população está cada vez mais consciente disso. Por exemplo, recentemente houve um caso de desvio de dinheiro na AGT relacionado com o IVA, e a população ficou completamente revoltada. Estávamos a falar com algumas pessoas que diziam: “Bom, quando havia dinheiro do petróleo, não se sentia tanto, porque o petróleo é uma economia de enclave, não havia esse impacto directo. Agora, quando roubam o dinheiro do IVA, estão a roubar o dinheiro dos mais pobres”.Isso mostra que a cobrança de impostos aumenta a consciência cívica. O imposto não é apenas um instrumento de arrecadação pública, mas também de participação cívica. E é a melhor forma de garantir uma democracia mais vibrante. A democracia precisa de receitas para funcionar, porque as instituições precisam de dinheiro, e esse dinheiro vem, em primeiro lugar, dos impostos.No seu trabalho encontra um resultado curioso: quando a economia não petrolífera cresce, a arrecadação de impostos fora do petróleo não aumenta. Como se explica isso?No caso específico de Angola, isso foi uma verdadeira surpresa para nós. O PIB não petrolífero é a base para a incidência dos impostos não petrolíferos. De acordo com a teoria económica, o aumento do PIB deveria levar ao aumento das receitas fiscais. Mas, em Angola, isso não aconteceu durante o período que analisámos (2008-2021).Durante esse período, as receitas fiscais não petrolíferas não acompanharam o crescimento do PIB não petrolífero. Isso é um paradoxo.E como se explica isso?Uma das razões prende-se com o facto de o governo ter concedido muitas isenções fiscais. Muitas empresas foram criadas e beneficiaram dessas isenções. Por exemplo, a Unitel, a maior empresa de telecomunicações de Angola, teve isenção de imposto industrial quando foi criada, e continua a ser uma das mais lucrativas do país. Até hoje, não sabemos se essa isenção já terminou, porque não há dados oficiais disponíveis.Essas isenções fiscais foram atribuídas de forma discricionária. Só em 2022 é que o governo aprovou o Código das Isenções Fiscais. Antes disso, qualquer ministério podia concedê-las. Foi então criada uma agência para este efeito, mas a Administração Geral Tributária não tem acompanhado,  ou, pelo menos, não há registos públicos das isenções concedidas.Essas isenções explicam a relação negativa entre o PIB não petrolífero e as receitas fiscais não petrolíferas. Infelizmente, a reforma tributária implementada pelo governo não abordou essa questão nem a redução da carga fiscal. E tudo foi feito na ânsia de atrair investimento privado, mas de forma pouco estruturada. Não há dados sobre o número de isenções concedidas. Procurámos essa informação junto da AGT, mas não conseguimos obtê-la. Enquanto o governo não se organizar neste sentido, essa relação negativa poderá persistir.A economia informal é um grande desafio em África e, claro, também em Angola. Que soluções existem, na sua opinião, para integrar mais trabalhadores e empresas no sistema formal de impostos?A economia informal em África é, em grande parte, consequência da má governação. A maioria das pessoas ou pequenos empresários não está na informalidade por vontade própria, estão por falta de opção.Dou-lhe um exemplo: em Angola, há muitos cidadãos que não têm bilhete de identidade. Hoje, o número de identificação fiscal (NIF) está ligado ao número do Bilhete de Identidade. Logo, quem não tem BI, não tem NIF e, por isso, não é reconhecido como contribuinte. Como é que essa pessoa vai formalizar o seu negócio?Isto revela falhas graves nas políticas públicas, quer no registo das pessoas, quer no registo da propriedade. Muitas propriedades não estão legalmente registadas: há pessoas que têm terrenos ou edifícios, mas não têm documentos legais que os comprovem. Essa falha obriga muitas pessoas à informalidade.E a informalidade não é sustentável. Se muitos desses trabalhadores e empresas fossem formalizados, isso representaria um aumento significativo nas receitas fiscais, quer em impostos sobre empresas e rendimento, quer em impostos indirectos.Francisco Paulo, uma última questão. Com base na sua investigação, que recomendações deixaria aos governos africanos para aumentarem a receita fiscal sem pôr em risco a estabilidade social e política?Analisámos a curva de Laffer, que mede a relação entre a taxa de impostos e a receita fiscal em termos monetários. E notámos que, no que toca ao imposto sobre empresas e aos impostos indirectos, muitos países africanos já atingiram o seu limite. Não há margem para aumentar ainda mais as taxas porque quem já paga impostos são sempre os mesmos, os formalizados. Isso gera uma sobrecarga injusta.A melhor forma de expandir a base tributária é formalizar a economia informal. Para isso, é essencial investir no registo civil das pessoas, no registo da propriedade e na educação. Isso incentivaria as pessoas a formalizarem os seus negócios.Os governos africanos devem canalizar os seus gastos públicos para a melhoria efectiva das condições de vida da população. Quando as pessoas percebem que os seus impostos estão a ser bem utilizados; quando vêem melhorias nas infra-estruturas, na saúde, na educação, estão mais dispostas a pagar impostos. E isso, por sua vez, pode contribuir para melhores índices de democracia em África.

I den nyeste episoden av i loopen får du en dyptgående samtale med Zaineb Al-Samarai, Idrettspresident, NIF, Anita Leirvik North, Byråd for kultur og næring (H), og Jannicke Aas, daglig leder i Vålerenga Samfunn.Med Danat Tekie som programleder utforsker vi hvordan idretten kan bygge broer i samfunnet, samt de reelle utfordringene rundt økonomiske barrierer for deltakelse. Gjestene deler verdifulle og ufiltrerte perspektiver og presenterer konkrete løsninger for å sikre at idretten forblir tilgjengelig for alle.En spennende samtale for alle som er opptatt av idrett og samfunnsutvikling!Husk å abonnere! Hosted on Acast. See acast.com/privacy for more information.

News includes the release of Elixir 1.18.2 with various enhancements and bug fixes, a new experimental SQL sigil for Ecto that brings automatic parameterized queries, a recent GOTO 2025 talk featuring Saša Jurić on code reviews. We talked with Jonatan Kłosko about his work on PythonX, a new library for executing Python code inside Elixir, the Fine library for working with C++ NIFs, and much more! Show Notes online - http://podcast.thinkingelixir.com/244 (http://podcast.thinkingelixir.com/244) Elixir Community News https://gigalixir.com/thinking (https://gigalixir.com/thinking?utm_source=thinkingelixir&utm_medium=shownotes) – Visit Gigalixir.com to sign up and get 20% off your first year. Or use the promo code "Thinking" during signup. https://github.com/elixir-lang/elixir/releases/tag/v1.18.2 (https://github.com/elixir-lang/elixir/releases/tag/v1.18.2?utm_source=thinkingelixir&utm_medium=shownotes) – Elixir 1.18.2 was released with enhancements to Code.Fragment and Regex, plus bug fixes for CLI, ExUnit, IEx.Autocomplete, and mix deps.update. https://github.com/elixir-lang/elixir/releases/tag/v1.18.1 (https://github.com/elixir-lang/elixir/releases/tag/v1.18.1?utm_source=thinkingelixir&utm_medium=shownotes) – Elixir 1.18.1 included bug fixes for Kernel, ExUnit.Case, mix compile.elixir, mix escript.build, and Mix.Shell, especially related to error handling and Windows compatibility. https://www.erlang.org/news/174 (https://www.erlang.org/news/174?utm_source=thinkingelixir&utm_medium=shownotes) – Erlang OTP 28 RC-1 is out with a new source Software Bill of Materials (SBOM) on the Github Releases page. https://github.com/elixir-dbvisor/sql (https://github.com/elixir-dbvisor/sql?utm_source=thinkingelixir&utm_medium=shownotes) – A new experimental SQL sigil for Ecto brings an extensible SQL parser to Elixir with automatic parameterized queries. https://groups.google.com/g/elixir-ecto/c/8MOkRFAdLZc (https://groups.google.com/g/elixir-ecto/c/8MOkRFAdLZc?utm_source=thinkingelixir&utm_medium=shownotes) – The experimental SQL sigil for Ecto is being discussed on the Elixir-Ecto mailing list. https://www.youtube.com/watch?v=AYUNI2Pm6_w (https://www.youtube.com/watch?v=AYUNI2Pm6_w?utm_source=thinkingelixir&utm_medium=shownotes) – New talk from GOTO 2025 with Saša Jurić and Adrienne Braganza Tacke on "Small PRs, Big Impact - The Art of Code Reviews." https://alchemyconf.com/ (https://alchemyconf.com/?utm_source=thinkingelixir&utm_medium=shownotes) – AlchemyConf is coming up March 31 - April 3 in Braga, Portugal. https://www.gigcityelixir.com/ (https://www.gigcityelixir.com/?utm_source=thinkingelixir&utm_medium=shownotes) – GigCity Elixir and NervesConf are happening in Chattanooga, TN, USA with NervesConf on May 8 and the main event on May 9-10. https://www.elixirconf.eu/ (https://www.elixirconf.eu/?utm_source=thinkingelixir&utm_medium=shownotes) – ElixirConf EU will be held May 15-16, 2025 in Kraków & Virtual. https://goatmire.com/#tickets (https://goatmire.com/#tickets?utm_source=thinkingelixir&utm_medium=shownotes) – Goatmire tickets are on sale now for the event happening September 10-12, 2025 in Varberg, Sweden. Do you have some Elixir news to share? Tell us at @ThinkingElixir (https://twitter.com/ThinkingElixir) or email at show@thinkingelixir.com (mailto:show@thinkingelixir.com) Discussion Resources https://dashbit.co/blog/dashbit-plans-2025 (https://dashbit.co/blog/dashbit-plans-2025?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/thewca/wca-live (https://github.com/thewca/wca-live?utm_source=thinkingelixir&utm_medium=shownotes) – Speed cubing software https://dashbit.co/blog/running-python-in-elixir-its-fine (https://dashbit.co/blog/running-python-in-elixir-its-fine?utm_source=thinkingelixir&utm_medium=shownotes) https://hexdocs.pm/pythonx/Pythonx.html (https://hexdocs.pm/pythonx/Pythonx.html?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/livebook-dev/pythonx (https://github.com/livebook-dev/pythonx?utm_source=thinkingelixir&utm_medium=shownotes) https://bsky.app/profile/josevalim.bsky.social/post/3liyrfvlth22c (https://bsky.app/profile/josevalim.bsky.social/post/3liyrfvlth22c?utm_source=thinkingelixir&utm_medium=shownotes) – Jose said “We said we will focus on interoperability for 2025 and we are ready to share the first results.” https://github.com/elixir-nx/fine (https://github.com/elixir-nx/fine?utm_source=thinkingelixir&utm_medium=shownotes) – “Fine” is a new package related to the elixir-nx organization. It's a C++ library enabling more ergonomic NIFs, tailored to Elixir. https://peps.python.org/pep-0703/ (https://peps.python.org/pep-0703/?utm_source=thinkingelixir&utm_medium=shownotes) – Discussion about removing the Python GIL Find us online - Message the show - Bluesky (https://bsky.app/profile/thinkingelixir.com) - Message the show - X (https://x.com/ThinkingElixir) - Message the show on Fediverse - @ThinkingElixir@genserver.social (https://genserver.social/ThinkingElixir) - Email the show - show@thinkingelixir.com (mailto:show@thinkingelixir.com) - Mark Ericksen on X - @brainlid (https://x.com/brainlid) - Mark Ericksen on Bluesky - @brainlid.bsky.social (https://bsky.app/profile/brainlid.bsky.social) - Mark Ericksen on Fediverse - @brainlid@genserver.social (https://genserver.social/brainlid) - David Bernheisel on Bluesky - @david.bernheisel.com (https://bsky.app/profile/david.bernheisel.com) - David Bernheisel on Fediverse - @dbern@genserver.social (https://genserver.social/dbern)

Dive into this episode of The Brand Called You with Prof. Anil Sahasrabudhe, a luminary in India's educational landscape. From his inspiring personal journey to his visionary role in leveraging technology for equitable and innovative learning, this discussion covers groundbreaking insights on India's National Education Policy, fostering innovation, and integrating the rich Indian Knowledge System into modern education.00:39- About Prof Anil Sahasrabudhe Professor Sahasrabudhe is the chairman of NETF, NBA, EC, NAAC and NIF. He is a distinguished figure in India's educational landscape.

Olá Bom Dia ALEGRIA! Munson here with the Good Morning Portugal! show, livestream & podcast... We start the show with the all-new 'Bom Dia Daily' - 20 minutes of news, weather, language, culture & wellbeing in Portugal, by way of an introduction today to...Lighthouse Consulting's Raquel and our mate Nuno Mendes, who'll be talking about the 'Power of the NIF', and how and when to use it, as well as providing their monthly business world update.Comments in the chat, pics & vids to WhatsApp (00 351) 913 590 303Get more at www.goodmorningportugal.com / Support the show and join the Portugal Club at www.gmpvip.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-good-morning-portugal-podcast-with-carl-munson--2903992/support.

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  AI for enhancing theranosticsTelix - Simon Wail @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Simon Wail from Telix about how AI may improve the use of PET scans in theranostics TAGS ANZSNM24,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,TELIX @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

In this special 200th episode of NucleCast, Jill Hruby, the Administrator of NNSA and Undersecretary of the Department of Energy for Nuclear Security, discusses the achievements and challenges faced by NNSA during her tenure, including the modernization of nuclear weapons, strengthening international partnerships, and the importance of infrastructure projects. Jill shares insights on the Strategic Posture Commission's recommendations, the plans for pit production, and the significance of the National Ignition Facility (NIF). She emphasizes the need for a renewed focus on nuclear IQ and offers advice for future leadership in the nuclear enterprise.Administrator Jill Hruby was Senate confirmed as the Under Secretary for Nuclear Security of the U.S. Department of Energy (DOE) and Administrator of the National Nuclear Security Administration in 2021.Administrator Hruby leads NNSA in achieving our Nation's nuclear security missions to sustain and fully understand our nuclear weapons stockpile; provide new technologies and procedures to lower cost and reduce the time to deliver all mission requirements; staying ahead of our adversaries; and developing advanced capabilities to enhance nuclear security, arms control, and Navy reactors.Prior to her nomination as Administrator, Ms. Hruby served as Director of Sandia National Laboratories from 2015-17 and has an extensive background in science and engineering spanning more than 40 years.Chapters00:00 Introduction to NNSA and Jill Hruby01:31 Reflecting on Achievements and Challenges04:34 Infrastructure Projects and Challenges10:18 Strategic Posture Commission Insights12:30 Pit Production Plans and Timelines16:31 NIF and Its Significance19:41 Increased Activity Across NNSA22:17 Advice for Future Leadership26:08 Wishes for the Nuclear Enterprise29:53 Parting Message and Future OutlookSocials:Follow on Twitter at @NucleCastFollow on LinkedIn: https://linkedin.com/company/nuclecastpodcastSubscribe RSS Feed: https://rss.com/podcasts/nuclecast-podcast/Rate: https://podcasts.apple.com/us/podcast/nuclecast/id1644921278Email comments and topic/guest suggestions to NucleCast@anwadeter.org

I això vol dir poder tenir un NIF propi per facilitar i agilitzar la gestió de situacions puntuals, o d'imponderables que sorgeixen i que han de poder resoldre's al moment, fins a la cerca de noves fonts d'ingressos a través de patrocinis o d'altres recursos. La nova comissió de Festa Major, presidida per Xavier Salmeron, creu que es pot aconseguir i que no seria cap novetat, tenint en compte que les comissions de Vilafranca i Vilanova tenen NIF propi. A la vegada, hi ha la consciència que la proposta podria esdevenir un precedent aplicable a d'altres comissions. Tot plegat amb l'objectiu que la comissió de Festa Major es pugui dedicar veritablement als aspectes troncals de la Festa, com son el seu desenvolupament, la seva difusió i coneixement, i la proposta d'iniciatives que la puguin fer encara més participativa i propera per als qui en són nouvinguts. Ens ho han explicat Xavier Salmeron, acompanyat de Maria Junyent, Gabri González i Irene Martinez. L'entrada La nova comissió de Festa Major es proposa com un dels objectius prioritaris poder gestionar-se com una associació per impulsar noves iniciatives ha aparegut primer a Radio Maricel.

Vackrar formuleringar á la Karin Boye strösslas det inte med i avsnitt #112 av Blåstället... Det blir en och annan svordom och harang (ursäkta kära lyssnare, vi försökte redigera med lite censur-toner men gav upp till slut) när Acke och Myran ska använda sin offentliga terapiplattform som är Blåstället för att försöka släppa ut lite frustrationsångor efter ett Annandagsderby som inte blev riktigt som någon med NIF i hjärtat hade önskat.Vi lider tillsammans. Vi kämpar tillsammans. Heja Nässjö!

Blåstället myser, hyllar, gnäller, skrattar och dricker lite gott (enligt tillförlitlig statistik drack ca 50% av de medverkande i podcasten vin vid inspelningstillfället) kvällen innan julafton. Annandagskänslor, torr Madeira, bandyläktarlångkalsongsinnovatörer (fanns inte tidigare som ord men nu gör det det) och Fansens Lirare är bara en del av vad som avhandlas.Trevlig lyssning och God Jul!

News includes Saša Jurić updating his project for "The Soul of Erlang and Elixir" talk with the latest technologies, the release of Phoenix LiveView RC 8 with exciting new features, ErrorTracker v0.5.0's enhancements for Ash applications, and the introduction of the NX MLX backend for Apple Silicon, offering efficient machine learning on Mac hardware. Plus, a new VS Code plugin called "Refactorex" brings robust refactoring capabilities to Elixir. We also interview Gonzalo Rodriguez about Tower, a vendor-agnostic error tracking and reporting tool in Elixir, discussing its creation, functionality, and how it simplifies error management across various services. And more! Show Notes online - http://podcast.thinkingelixir.com/232 (http://podcast.thinkingelixir.com/232) Elixir Community News https://x.com/sasajuric/status/1863889108449337415 (https://x.com/sasajuric/status/1863889108449337415?utm_source=thinkingelixir&utm_medium=shownotes) – Saša Jurić updated the project used in his "The Soul of Erlang and Elixir" talk, rewriting it with the latest versions of Erlang, Elixir, & Phoenix. https://github.com/sasa1977/souloferlangandelixir (https://github.com/sasa1977/soul_of_erlang_and_elixir?utm_source=thinkingelixir&utm_medium=shownotes) – The updated GitHub project for "The Soul of Erlang and Elixir" talk, now using the latest technologies. https://www.youtube.com/watch?v=JvBT4XBdoUE (https://www.youtube.com/watch?v=JvBT4XBdoUE?utm_source=thinkingelixir&utm_medium=shownotes) – Saša Jurić's 2019 talk "The Soul of Erlang and Elixir" is available on YouTube. https://github.com/phoenixframework/phoenixliveview/blob/main/CHANGELOG.md#100-rc8-2024-12-02 (https://github.com/phoenixframework/phoenix_live_view/blob/main/CHANGELOG.md#100-rc8-2024-12-02?utm_source=thinkingelixir&utm_medium=shownotes) – Phoenix LiveView RC 8 is out, with new features like extended HEEx syntax and more. From RC7, there is support for targeting inner and closest query selectors in JS commands. https://x.com/crbelaus/status/1861450830181720333 (https://x.com/crbelaus/status/1861450830181720333?utm_source=thinkingelixir&utm_medium=shownotes) – ErrorTracker v0.5.0 release includes support for Ash applications, better mobile experience, and more. https://bsky.app/profile/samrat.me/post/3lbzwr7gxmk2q (https://bsky.app/profile/samrat.me/post/3lbzwr7gxmk2q?utm_source=thinkingelixir&utm_medium=shownotes) – The NX MLX backend for Apple Silicon is announced, offering efficient machine learning on Apple hardware. https://github.com/elixir-nx/emlx (https://github.com/elixir-nx/emlx?utm_source=thinkingelixir&utm_medium=shownotes) – GitHub repository for NX MLX, Elixir support for the Apple MLX machine learning framework on Apple Silicon. MLX is designed by Apple for efficient machine learning on MacOS hardware. https://github.com/cocoa-xu/nif_call (https://github.com/cocoa-xu/nif_call?utm_source=thinkingelixir&utm_medium=shownotes) – Cocoa's nif_call package allows calling Elixir functions from inside a NIF. https://bsky.app/profile/zachdaniel.dev/post/3lc2leowiek26 (https://bsky.app/profile/zachdaniel.dev/post/3lc2leowiek26?utm_source=thinkingelixir&utm_medium=shownotes) – Zach Daniel's ElixirConf EU talk on the Ash framework is available on YouTube. https://www.youtube.com/watch?v=vjnPjrCF4rs (https://www.youtube.com/watch?v=vjnPjrCF4rs?utm_source=thinkingelixir&utm_medium=shownotes) – Ash: The Story of a Function by Zach Daniel explains why Ash exists and the problems it solves. https://github.com/gp-pereira/refactorex (https://github.com/gp-pereira/refactorex?utm_source=thinkingelixir&utm_medium=shownotes) – New VS Code plugin "Refactorex" by Gabriel Pereira for refactoring Elixir code with several built-in refactorings. https://adventofcode.com/2024/ (https://adventofcode.com/2024/?utm_source=thinkingelixir&utm_medium=shownotes) – Advent of Code is active, with people participating using their favorite programming languages. https://notes.club (https://notes.club?utm_source=thinkingelixir&utm_medium=shownotes) – A platform that hosts a frontend of Livebooks on GitHub, organized by author, likes, and tags, useful for exploring how people are solving Advent of Code problems in Elixir. https://github.com/ljgago/kino_aoc (https://github.com/ljgago/kino_aoc?utm_source=thinkingelixir&utm_medium=shownotes) – A GitHub repository for a Livebook Smart Cell which aids in solving Advent of Code directly from Livebook. https://github.com/nettinho/smaoc (https://github.com/nettinho/smaoc?utm_source=thinkingelixir&utm_medium=shownotes) – Another Livebook Smart Cell repository on GitHub for Advent of Code that facilitates problem interaction within Livebook. Do you have some Elixir news to share? Tell us at @ThinkingElixir (https://twitter.com/ThinkingElixir) or email at show@thinkingelixir.com (mailto:show@thinkingelixir.com) Discussion Resources https://www.mimiquate.com/blog/tower-universal-and-agnostic-elixir-exception-tracking (https://www.mimiquate.com/blog/tower-universal-and-agnostic-elixir-exception-tracking?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mimiquate/tower (https://github.com/mimiquate/tower?utm_source=thinkingelixir&utm_medium=shownotes) – The root Tower project https://github.com/mimiquate/tower_email (https://github.com/mimiquate/tower_email?utm_source=thinkingelixir&utm_medium=shownotes) – Email sending when error encountered (uses Swoosh) https://github.com/mimiquate/towererrortracker (https://github.com/mimiquate/tower_error_tracker?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mimiquate/tower_sentry (https://github.com/mimiquate/tower_sentry?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mimiquate/tower_slack (https://github.com/mimiquate/tower_slack?utm_source=thinkingelixir&utm_medium=shownotes) Pull requests for the mentioned Bandit updates https://github.com/mtrudel/bandit/pull/411 (https://github.com/mtrudel/bandit/pull/411?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mtrudel/bandit/pull/417 (https://github.com/mtrudel/bandit/pull/417?utm_source=thinkingelixir&utm_medium=shownotes) https://github.com/mtrudel/bandit/pull/420 (https://github.com/mtrudel/bandit/pull/420?utm_source=thinkingelixir&utm_medium=shownotes) Guest Information https://x.com/grzuy (https://x.com/grzuy?utm_source=thinkingelixir&utm_medium=shownotes) – on Twitter/X https://github.com/grzuy/ (https://github.com/grzuy/?utm_source=thinkingelixir&utm_medium=shownotes) – on Github https://bsky.app/profile/grzuy.bsky.social (https://bsky.app/profile/grzuy.bsky.social?utm_source=thinkingelixir&utm_medium=shownotes) – on Bluesky Find us online Message the show - Bluesky (https://bsky.app/profile/thinkingelixir.com) Message the show - X (https://x.com/ThinkingElixir) Message the show on Fediverse - @ThinkingElixir@genserver.social (https://genserver.social/ThinkingElixir) Email the show - show@thinkingelixir.com (mailto:show@thinkingelixir.com) Mark Ericksen on X - @brainlid (https://x.com/brainlid) Mark Ericksen on Bluesky - @brainlid.bsky.social (https://bsky.app/profile/brainlid.bsky.social) Mark Ericksen on Fediverse - @brainlid@genserver.social (https://genserver.social/brainlid) David Bernheisel on Bluesky - @david.bernheisel.com (https://bsky.app/profile/david.bernheisel.com) David Bernheisel on Fediverse - @dbern@genserver.social (https://genserver.social/dbern)

Resumen Ejecutivo: Iniciativa Fiscal 2025 y Cierre Fiscal 2024 Este podcast resume los puntos clave de la Iniciativa Fiscal 2025 y estrategias para el cierre fiscal 2024, con base en las presentaciones de C.P.C. Jorge Ayax Cabello Hdz. y Mario Orlando Beltrán López. I. Iniciativa Fiscal 2025: A. Sin Reforma Fiscal: La presidenta Claudia Sheinbaum ha reiterado que no habrá reforma fiscal. El enfoque será reforzar la fiscalización para aumentar la recaudación. B. Multas y Recargos: Se mantienen las tasas de recargos mensuales de 2023. Continúa la facilidad de reducción del 50% de la multa al pagar contribuciones omitidas y accesorios antes del acta final de visita domiciliaria. C. Estímulos Fiscales: Se mantienen la mayoría de los estímulos fiscales del Art. 16. Se modifica el estímulo de devolución del IEPS por diésel para actividades agropecuarias o silvícolas, requiriendo acreditar su uso exclusivo en maquinaria para dichas actividades. Se elimina el estímulo al derecho por utilidad compartida en la Ley de Ingresos sobre Hidrocarburos. Se incorporan estímulos para el Régimen Simplificado de Confianza (Resico) en actividades agrícolas, ganaderas, silvícolas o pesqueras, y para proyectos de inversión en cine, teatro, literatura, artes visuales, danza y música. Se suspende el estímulo al deporte de alto rendimiento. D. Beneficios Fiscales ISR: Se adicionan beneficios para personas físicas en Resico dedicadas a actividades agropecuarias, con ingresos superiores a 900 mil pesos. Se aumentan los montos máximos para estímulos fiscales a las artes y el cine. E. Cancelación de Comprobantes Fiscales: Se establece en ley la posibilidad de cancelar CFDI hasta el último día del mes de la declaración anual del ejercicio fiscal en que se expidió, con aceptación del receptor. F. Estímulo Fiscal Transitorio: Personas físicas y morales con ingresos totales no superiores a 35 millones de pesos podrán beneficiarse de un estímulo fiscal que alivia cargas por multas, recargos y gastos de ejecución, excluyendo a quienes recibieron condonaciones previas. El estímulo aplica a conceptos como multas fiscales, aduaneras y de comercio exterior, recargos y gastos de ejecución relacionados con contribuciones federales y cuotas compensatorias. No aplica a créditos fiscales remitidos al SAT para cobro, ni a pagos en especie o compensación. Para aplicar, se debe regularizar contribuciones omitidas de ejercicios 2023 o anteriores, pagando en una sola exhibición antes del 31 de diciembre de 2025, entre otros requisitos. Se excluye a contribuyentes con sentencia condenatoria firme por delitos fiscales y a los enlistados en los Artículos 69-B y 69-B Bis del Código Fiscal de la Federación. G. Subsidio al Empleo 2024: Se implementa un nuevo subsidio al empleo para trabajadores con ingresos mensuales no superiores a $9,081.00 MXN. El monto del subsidio es del 11.82% del valor mensual de la UMA. Se excluyen las primas de antigüedad, retiro, indemnizaciones y otros pagos por separación. El subsidio se aplica contra el ISR mensual del trabajador. Si el impuesto a cargo es menor al subsidio, la diferencia no se aplica a futuro ni se entrega al trabajador. Se detallan los cálculos para pagos en periodos menores a un mes y en una sola exhibición que abarquen varios meses. Los trabajadores con múltiples empleadores deben elegir a cuál aplicar el subsidio. Se generan dudas sobre la aplicación del subsidio a trabajadores que ganan el salario mínimo, ya que el SAT afirma que "al no existir impuesto a cargo" no les aplica el subsidio, aunque la ley no lo exime del ISR. H. Consideraciones para 2025: Se debe considerar la entrada en vigor de la multa por no habilitar el buzón tributario a partir del 01 de enero de 2025. Finaliza la facilidad para contribuyentes del sector de hidrocarburos de expedir CFDI Global hasta el 31 de diciembre de 2024. I. Identificación del Beneficiario Controlador: Se recuerda la obligación introducida en 2023 de identificar al "beneficiario controlador" en la contabilidad de personas morales y otras entidades jurídicas, con multas por incumplimiento que van desde $500,000.00 hasta $2,000,000.00 MXN. El SAT puede cancelar sellos digitales de empresas con socios o accionistas que son beneficiarios controladores y cometan infracciones. II. Estrategias para el Cierre Fiscal 2024: A. Antes de Iniciar: Verificar la expedición de todos los CFDI, incluyendo ingresos, anticipos, globales y pagos. Activar el buzón tributario, localizar el domicilio fiscal y cumplir con las obligaciones fiscales, incluyendo la contabilidad electrónica. Revisar diferencias en impuestos y retenciones, así como las opiniones de cumplimiento de SAT, IMSS, INFONAVIT e INFONACOT. Revisar avisos, manuales y declaraciones. Tener los contratos de servicios, adquisiciones y laborales en orden. Contar con nóminas impresas y firmadas con requisitos de la LFT. Integrar comisiones LFT, PTU, comisión mixta, reglamentación de vacaciones y el Salario Base de Cotización. Revisar SUA-IDSE-SIPARE. B. Impuesto al Valor Agregado (IVA): Cruzar IVA trasladado entre CFDI y declaraciones. Verificar requisitos de acreditamiento. Distinguir actividades gravadas al 16%, 0%, exentas y no objeto en los CFDI. Revisar objeto de impuesto y formas de pago, incluyendo compensación. Asegurar el entero de retenciones en el mes siguiente para el acreditamiento. Enviar la DIOT y preparar la DIOC. C. Impuesto Especial sobre Producción y Servicios (IEPS): Expedir comprobantes fiscales. Cumplir con el artículo 19 II LIEPS. Presentar declaraciones mensuales y anuales. Enviar informativas Multi-IEPS mensuales, trimestrales y para entidades federativas. D. Impuestos Estatales: Revisar bases de impuestos estatales para nómina y hospedaje. Revisar la legislación de cada entidad federativa sobre el impuesto sobre nóminas. Cruzar información con CFDI-n y EMA. E. Personas Morales: Revisar el objeto social en relación a las actividades realizadas durante el ejercicio. Contar con libro de actas de asamblea ordinarias y accionarias protocolizado, y libro de accionistas actualizado. Autorizar en actas de asamblea movimientos relevantes que afecten la vida social, contable y fiscal. Contar con contratos de operaciones relevantes que coincidan con resolutivos de actas de asamblea. Asegurar la fecha cierta de los contratos. Celebrar la asamblea general ordinaria de accionistas para aprobar los estados financieros. Registrar todas las operaciones económicas con base en NIF. Realizar conciliaciones de efectivo, bancarias, de moneda extranjera, de clientes, proveedores y otros. Valuar inventarios y devengar pagos anticipados. Identificar la adquisición de activos fijos y determinar su valor depreciable y residual. Revisar IVA acreditable y trasladado, depósitos en garantía y otras cuentas. Integrar y aplicar pagos por cuenta de terceros. Revisar requisitos para deducción de combustibles (CRE). Registrar deducciones en cuentas de resultados y de orden. Cruzar y enterar retenciones diversas. Integrar pagos de sueldos y salarios, conciliándolos con la contabilidad y el visor de nómina. Conciliar pasivos al 31 de diciembre para quienes acumulan con base en percepción efectiva. F. Personas Físicas: Revisar el estatus en el RFC. Realizar un diagnóstico de ingresos declarados vs. los que corresponden declarar. Revisar erogaciones, incluyendo deducibles y no deducibles, depósitos bancarios y pagos con tarjeta de crédito. Considerar datos informativos de préstamos, donativos, premios, viáticos, enajenación de casa habitación, herencias y legados. G. Sugerencias y Recomendaciones: Evitar prácticas indebidas que puedan generar revisiones del SAT. Tener especial cuidado con las operaciones del mes de diciembre. Preparar la información de deudores y acreedores diversos. Elaborar papeles de trabajo y documentar las operaciones con contratos con fecha cierta. III. Conclusión: Tanto la Iniciativa Fiscal 2025 como las estrategias para el cierre fiscal 2024 se enfocan en el cumplimiento de las obligaciones fiscales y la correcta aplicación de los beneficios y estímulos disponibles. Es fundamental que los contribuyentes se mantengan informados sobre las modificaciones y realicen una planificación adecuada para evitar contingencias fiscales.

In this episode, Josh and Kalie from ExpatsEverywhere dive into a Q&A format, addressing various questions from their patrons about living in Portugal. They cover topics such as understanding taxi lights, navigating phone plans, the timing for obtaining a NIF and bank account, hiring housekeepers, visa income requirements, and the differences between D7 and D8 visas. They also discuss language courses for citizenship, finding accommodation, renewing temporary residency while applying for citizenship, and compare dental care in Portugal to the US. The episode concludes with insights on EU citizenship and the golden visa investment maintenance.MALO Clinic: https://www.maloclinics.com/en/general-appointment-form?utm_source=expats_everywhere?utm_medium=social_partnership?utm_campaign=BF_NOV ★ Support this podcast on Patreon ★

May I introduce you to my husband.nnIf you are introducing a person by their first name, without including their title, you add an ‘a' before the name:nnExample: Le presento a Ray Blakney -> May I introduce you to Ray Blakney.nnIf you are introducing a person with their title you add either an ‘a la' if they are female or ‘al', spelled ‘A-L' if they are male. That is just contraction of ‘a el'.nnExample: Le presento a la doctora Sánchez -> May I introduce you to Dr. Sánchez.nnNow, repeat all the following phrases out loud, but add the word ‘le presento' at the beginning of each one.nnExample: A mi hijo -> Le presento a mi hijo.nnFind more practice exercises in this blog post after listening to the episode.nnDon't forget to subscribe here, rate 5 stars, and leave a review!"}" data-sheets-userformat= "{"2":14465,"3":{"1":0,"3":1},"10":1,"14":{"1":3,"3":1},"15":"Arial","16":10}"> Let's practice introducing others. To introduce others we will use the phrase ‘le presento' which means ‘may I introduce you to'. This is followed by my ‘mi' if you are introducing a family member, since you are implying a relationship to you. Example: Le presento a mi esposo -> May I introduce you to my husband. If you are introducing a person by their first name, without including their title, you add an ‘a' before the name: Example: Le presento a Ray Blakney -> May I introduce you to Ray Blakney. If you are introducing a person with their title you add either an ‘a la' if they are female or ‘al', spelled ‘A-L' if they are male. That is just contraction of ‘a el'. Example: Le presento a la doctora Sánchez -> May I introduce you to Dr. Sánchez. Now, repeat all the following phrases out loud, but add the word ‘le presento' at the beginning of each one. Example: A mi hijo -> Le presento a mi hijo. Find more practice exercises in this blog post after listening to the episode. Don't forget to subscribe here, rate 5 stars, and leave a review!

Jasmine Mund, mechanical engineer, gives today's Fusion News update - summarizing the major recent headlines in fusion energy. Links to all of the stories mentioned are included below. 1. Groundbreaking research at NSIRC and Lancaster University set to transform fusion reactor development https://www.cambridgenetwork.co.uk/news/groundbreaking-research-nsirc-and-lancaster-university-set-transform-fusion-reactor 2. Multinational fusion energy project marks completion of its most complex magnet system https://phys.org/news/2024-07-multinational-fusion-energy-complex-magnet.html 3. ITER fusion reactor hit by massive decade-long delay and €5bn price hike https://physicsworld.com/a/iter-fusion-reactor-hit-by-massive-decade-long-delay-and-e5bn-price-hike/ Bonus: What next: Further implosion space exploration on the path to NIF extended yield capability https://pubs.aip.org/aip/pop/article/31/6/062712/3299549/What-next-Further-implosion-space-exploration-on?searchresult=1 Nuclear fusion challenges: Low pressure, high temperature, and the electromagnetic field https://www.power-technology.com/sponsored/nuclear-fusion-challenges-low-pressure-high-temperature-and-the-electromagnetic-field/ FIA Launches 2024 Supply Chain Report https://www.fusionindustryassociation.org/fia-launches-2024-supply-chain-report/ Fusion Industry Association and The Fusion Cluster Lay Out Strategic Priorities Ahead of UK Election https://www.fusionindustryassociation.org/fusion-industry-association-and-the-fusion-cluster-lay-out-strategic-priorities-ahead-of-uk-election/

If you're looking to move to Portugal + need to know more about how to get here on the D7 retirement (or passive income) visa, look no further. As a follow up to our last episode overview, Mark + I go in depth on the actual application requirements one-by-one and give you some big picture perspective about WHY they are asking you for this stuff + how to best position yourself for an approval on your visa application. Key Resources: ⁠Portugal Junkies Resources⁠ (1:1 Calls, Free Templates, Referrals for NIF, Bank Account + Lease Reviews) ⁠VFS Global Website⁠ ⁠AmericansandFriends PT Facebook Group⁠ ⁠Idealista Website FREE D7 Personal Statement Template

If you're looking to move to Portugal + need to know more about how to get here on the D7 retirement (or passive income) visa, look no further. As a follow up to our last episode overview, Mark + I go in depth on the actual application requirements one-by-one and give you some big picture perspective about WHY they are asking you for this stuff + how to best position yourself for an approval on your visa application. Key Resources: ⁠⁠Portugal Junkies Resources⁠⁠ (1:1 Calls, Free Templates, Referrals for NIF, Bank Account + Lease Reviews) ⁠⁠VFS Global Website⁠⁠ D7 Documentation Checklist D7 Application ⁠⁠AmericansandFriends PT Facebook Group⁠⁠ ⁠⁠Idealista Website⁠ ⁠FREE D7 Personal Statement Template

If you're looking to move to Portugal + need to know more about how to get here on the D7 retirement (or passive income) visa, look no further. Mark + I give a high level overview of the process, timelines and how to prepare to put your best self forward in your application. Stay tuned for the next two episodes where we go in depth on the actual application requirements one-by-one and give you some big picture perspective about WHY they are asking you for this stuff! Key Resources: Portugal Junkies Resources (1:1 Calls, Free Templates, Referrals for NIF, Bank Account + Lease Reviews) VFS Global Website AmericansandFriends PT Facebook Group Idealista Website

In neurocritical care, the initial evaluation is often fast paced, and assessment and management go hand in hand. History, clinical examination, and workup should be obtained while considering therapeutic implications and the need for lifesaving interventions. In this episode, Aaron Berkowitz, MD, PhD FAAN, speaks with Sarah Wahlster, MD, an author of the article “The Neurocritical Care Examination and Workup,” in the Continuum June 2024 Neurocritical Care issue. Dr. Berkowitz is a Continuum® Audio interviewer and professor of neurology at the University of California San Francisco, Department of Neurology and a neurohospitalist, general neurologist, and a clinician educator at the San Francisco VA Medical Center and San Francisco General Hospital in San Francisco, California. Dr. Wahlster is an associate professor of neurology in the departments of neurology, neurological surgery, and anesthesiology and pain medicine at Harborview Medical Center, University of Washington in Seattle, Washington. Additional Resources Read the article: The Neurocritical Care Examination and Workup Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Guest: @SWahlster Full Episode Transcript Sarah Wahlster, MD   Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, a companion podcast to the journal. Continuum Audio features conversations with the guest editors and authors of Continuum, who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article by clicking on the link in the Show Notes. Subscribers also have access to exclusive audio content not featured on the podcast. As an ad-free journal entirely supported by subscriptions, if you're not already a subscriber, we encourage you to become one. For more information on subscribing, please visit the link in the Show Notes. AAN members: stay tuned after the episode to hear how you can get CME for listening.  Dr Berkowitz: This is Dr Aaron Berkowitz, and today I'm interviewing Dr Sarah Wahlster about her article on examination and workup of the neurocritical care patient, which is part of the June 2024 Continuum issue on neurocritical care. Welcome to the podcast, Dr Wahlster. Can you please introduce yourself to the audience? Dr Wahlster: Thank you very much, Aaron. I'm Sarah Wahlster. I'm a neurologist and neurontensivist at Harborview Medical Center at the University of Washington. Dr Berkowitz: Well, Sarah and I know each other for many, many years. Sarah was my senior resident at Mass General and Brigham and Women's Hospital. Actually, Sarah was at my interview dinner for that program, and I remember meeting her and thinking, “If such brilliant, kind, talented people are in this program, I should try to see if I can find my way here so I can learn from them.” So, I learned a lot from Sarah as a resident, I learned a lot from this article, and excited for all of us to learn from Sarah, today, talking about this important topic. So, to start off, let's take a common scenario that we see often. We're called to the emergency room because a patient is found down, unresponsive, and neurology is called to see the patient. So, what's running through your mind? And then, walk us through your approach as you're getting to the bedside and as you're at the bedside. Dr Wahlster: Yeah, absolutely. This was a fun topic to write about because I think this initial kind of mystery of a patient and the initial approach is something that is one of the puzzles in neurology. And I think, especially if you're thinking about an emergency, the tricky part is that the evaluation and management go hand in hand. The thinking I've adapted as a neurointensivist is really thinking about “column A” (what is likely?) and “column B” (what are must-not-miss things?). It's actually something I learned from Steve Greenberg, who was a mutual mentor of us - but he always talked me through that. There's always things at the back of your head that you just want to rule out. I do think you evaluate the patient having in mind, “What are time-sensitive, critical interventions that this patient might need?” And so, I think that is usually my approach. Those things are usually anything with elevated intracranial pressure: Is the patient at risk of herniating imminently and would need a neurosurgical intervention, such as an EVD or decompression? Is there a neurovascular emergency, such as an acute ischemic stroke, a large-vessel occlusion, a subarachnoid hemorrhage that needs emergent intervention? And then other things you think about are seizures, convulsive/nonconvulsive status, CNS infection, spinal cord compression. But I think, just thinking about these pathologies somewhere and then really approaching the patient by just, very quickly, trying to gather as much possible information through a combination of exam and history. Dr Berkowitz: Great. So, you're thinking about all these not-to-miss diagnoses that would be life-threatening for the patient and you're getting to the bedside. So, how do you approach the exam? Often, this is a different scenario than usual, where the patient's not going to be able to give us a history or maybe necessarily even participate in the exam, and yet, as you said, the stakes are high to determine if there are neurologic conditions playing into this patient's status. So, how do you approach a patient at the bedside? Dr Wahlster: So, I think first step in an ICU setting (especially if the patient has a breathing tube) is you think about any confounders (especially sedation or metabolic confounders) - you want to remove as soon as possible, if able. I think as you do the exam, you try to kind of incorporate snippets of the history and really try to see - you know, localize the problem. And also kind of see, you know, what is the time course of the deterioration, what is the time course of the presentation. And that is something I actually learned from you. I know you've always had this framework of “what is it, where is it?” But I think in terms of just a clinical exam, I would look at localizing signs. I think, in the absence of being able to do the full head-to-toe neuro exam and interact with the patient, you really try to look at the brainstem findings. I always look at the eyes right away and look at, I think, just things like, you know, the gaze (how is it aligned? is there deviation? is there a skew? what do the pupils look like? [pupillary reactivity]). I think that's usually often a first step - that I just look at the patient's eyes. I think other objective findings, such as brainstem reflexes and motor responses, are also helpful. And then you just look whether there's any kind of focality in terms of - you know, is there any difference in size? But I think those are kind of the imminent things I look at quickly. Dr Berkowitz: Fantastic. Most of the time, this evaluation is happening kind of en route to the CT scanner or maybe a CT has already happened. So, let's say you're seeing a patient who's found down, the CT has either happened or you asked for it to happen somewhat quickly after you've done your exam, and let's say it's not particularly revealing early on. What are the sort things on your exam that would then push you to think about an MRI, a lumbar puncture, an EEG? You and I both spend time in large community hospitals, right, where “found down” is one of the most common chief concerns. In many cases, there isn't something to see on the CT or something obvious in the initial labs, and the question always comes up, “Who gets an MRI? Who gets an LP? Who gets an EEG?” - and I'm not sure I have a great framework for this. Obviously, you see focality on your exam, you know you need to look further. But, any factors in the history or exam that, even with a normal CT, raise your suspicion that you need to go further? Dr Wahlster: It's always a challenge, especially at a community hospital, because some of these patients come in at 1 AM where the EEG is not imminently available. But I think - let's say the CT scan is absolutely normal and doesn't give me a cause, but as an acute concerning deterioration, I think both EEG and LP would cross my mind. MRI I kind of see a little bit as a second-day test. I think there's very rare situation where an acute MRI would inform my imminent management. It's very informative, right, because you can see very small-vessel strokes. We had this patient that actually had this really bad vasculitis and we were able to see the small strokes everywhere on the MRI the day later, or sometimes helps you visualize acute brainstem pathology. But I think, even that - if you rule out a large-vessel occlusion on your CTA, there's brainstem pathology that is not imminently visible on the CT - it's nothing you need to go after. So, I do think the CT is a critical part of that initial eval, and whereas I always admire the neurological subspecialties, such as movements, where you just – like, your exam is everything. I think, to determine these acute time-sensitive interventions, the CT is key. And also, seeing a normal CT makes me a little less worried. You always look at these “four H” (they're big hypodensity, hyperdensity, any shift; is there hydrocephalus or herniation). I think if I don't have an explanation, my mind would imminently jump to seizure or CNS infection, or sometimes both. And I think then I would really kind of - to guide those decisions and whether I want to call in the EEG tech at 2 AM - I would, you know, again, look at the history and exam, see if there's any gaze deviation, tongue biting, incontinence - anything leading up towards seizure. I think, though, even if I didn't have any of those, those would strengthen my suspicion. If I really, absolutely don't have an explanation and the patient off sedation is just absolutely altered, I would still advocate for an EEG and maybe, in the meantime, do a small treatment trial. And I think with CNS infection - obviously, there are patients that are high risk for it - I would try to go back and get history about prodromes and, you know, look at things like the white count, fevers, and all of that. But again, I think if there's such a profound alteration in neurologic exam, there's nothing in the CT, and there's no other explanation, I would tend to do these things up front because, again, you don't want to miss them. Dr Berkowitz: Yeah, perfect. So many pearls in there, but one I just want to highlight because I'm not sure I've heard the mnemonic - can you tell us the four Hs again of sort of neurologic emergencies on CT? Dr Wahlster: Yeah. So, it's funny; for ages - I'm actually not sure where that's coming from, and I learned it from one of my fellows, one of our neurocritical care fellows - he's a fantastic teacher and he would teach our EM and anesthesia residents about it and his approach to CT. But yeah, the four H - he was always kind of like, “Look at the CT. Do you see any acute hypodensities, any hyperdensities?” And hypodensities would be involving infarct or edema; hyperdensities would be, most likely, hemorrhage (sometimes calcification or other things). Then, “Do you see hydrocephalus?” (because that needs an intervention). And, “Look at the midline structures and the ventricles.” And then, “Do you see any signs of herniation?” And he would go through the different types of herniation. But I thought that's a very good framework for looking at the “noncon” and just identifying critical pathology that needs some intervention. Dr Berkowitz: Yeah – so, hypodensity, hyperdensity, herniation, hydrocephalus. That's a good one – the four Hs; fantastic. Okay. So, a point that comes up a few times in your article - which I thought was very helpful to walk through and I'd love to pick your brain about a little bit – is, which patients need to be intubated for a neurologic indication? So, often we do consultations in medical, surgical ICUs; patients are intubated for medical respiratory reasons, but sometimes patients are intubated for neurologic reasons. So, can you walk us through your thinking on how to decide who needs to be intubated for the concern of depressed level of consciousness? Dr. Wahlster: It's an excellent question, and I think I would bet there's a lot of variation in practice and difference in opinion. There was actually the 2020 ESICM guidelines kind of commented on it, and those are great guidelines in terms of just intubation, mechanical ventilation of patients, and just acknowledging how there is a lack of really strong evidence. I would say the typical mantra (“GCS 8, intubate”) has been proposed in the trauma literature. And at some point, I actually dug into this to look behind the evidence, and there's actually not as much evidence as it's been put forth in guidelines and that kind of surprised me - that was just recently. I was like, “Actually, let me look this up.” I would say I didn't find a ton of strong evidence for it. I would say, as neurologist – you know, I'm amazed because GCS, I think is a - in some ways, a good tool to track things because it's so widely used across the board. But I would say, as neurologists, we all know that it sometimes doesn't account for some sort of nuances; you know, if a patient is aphasic, if a patient has an eyelid-opening apraxia - it can always be a little confounded. I'm amazed that GCS is still so widely used, to be frank. But I would say there is some literature - some school of thought - that maybe just blindly going by that mantra could be harmful or could not be ideal. I would say – I mean, I look at the two kind of functional things: oxygenation and ventilation. I think, in a neuro patient, you always think about airway protection or the decreased level of consciousness being a major issue (What is truly airway protection? Probably a mix of things). Then there's the issue of respiratory centers and respiratory drive - I think those are two issues you think about. But ultimately, if it leads to insufficient oxygenation - hypoxia early on is bad and that's been shown in several neurologic acute brain injuries. I think you also want to think about ventilation, especially if the mental status is poor to the point that the PCO2 elevates, that could also augment an ICP or exacerbate an ICP crisis. Or sometimes, I think there's just dysregulation of ventilation and there's hyperventilation to the point that the PCO2 is so low that I worry about cerebral vasoconstriction. So, I worry about these markers. I think, the oxygenation, I usually just kind of initially track on the sats. Sometimes, if the patient is profoundly altered, I do look at an arterial blood gas. And then there are things like breathing sounds (stridor, stertor [the work of breathing]). And I think something that also makes me have a lower threshold to intubate is if I'm worried and I want to scan, and I'm worried that the patient can't tolerate it - I want an imminent scan to just see why the patient is altered, or seizing, or presenting a certain way. Dr Berkowitz: All great pearls for how to think through this. Yeah - it's hard to think of hard and fast rules, and you can get to eight on the GCS in many different ways, as you said, some of which may not involve the respiratory mechanics at all. So, that's a helpful way of thinking about it that involves both the mental state, kind of the tracheal apparatus and how it's being managed by the neurologic system, and also the oxygen and carbon dioxide (sort of, respiratory parameters) – so, linking all those together; that's very helpful. And, related question – so, that's sort of for that patient with central nervous system pathology, who we're thinking about whether they need to be intubated for a primary neurologic indication. What about from the acute neuromuscular perspective (so, patients with Guillain-Barré syndrome or myasthenic crisis); how do you think about when to intubate those patients? Dr Wahlster: Yeah, absolutely - I think that's a really important one. And I think especially in a patient that is rapidly progressing, you always kind of think about that, and you want them in a supervised setting, either the ER or the ICU. I mean, there's some scores - I think there's the EGRIS score; there's some kind of models that predict it. I would say, the factors within that model, and based on my experience, often the pace of progression of reflex motor syndrome. I often see things like, kind of, changes in voice. You know, myasthenia, you look at things like head extension, flexion - those are the kind of factors. I would say there's this “20/30/40 rule” about various measures of, like, NIF and vital capacities, which is great. I would say in practice, I sometimes see that sometimes the participation in how the NIF is obtained is a little bit funky, so I wouldn't always blindly go by these numbers but sometimes it's helpful to track them. If you get a reliable kind of sixty and suddenly it drops to twenty, that makes me very concerned. But I would say, in general, it's really a little bit the work of breathing - looking at how the patient looks like. There's also (at some point) ABG abnormalities, but we always say, once those happen, you're kind of later in the game, so you should really - I think anyone that is in respiratory distress, you should think about it and have a low threshold to do it, and, at a minimum, monitor very closely. Dr Berkowitz: Yeah, we have those numbers, but so often, our patients who are weak, from a neuromuscular perspective, often have facial and other bulbar weakness and can't make a seal on the device that is used to check these numbers, and it can look very concerning when the patient may not, or can be a little bit difficult to interpret. So, I appreciate you giving us sort of the protocol and then the pearls of the caveats of how to interpret them and going sort of back to basics. So, just looking at the patient at the bedside and how hard they are working to breathe, or how difficult it is for them to clear their secretions from bulbar weakness. Moving on to another topic, you have a really wonderful section in your article on detecting clinical deterioration in patients in the neuro ICU. Many patients in the neuro ICU - for example, due to head trauma or large ischemic stroke or intracerebral hemorrhage, subarachnoid hemorrhage, or status epilepticus - they can't communicate with us to tell us something is getting worse, and they can't (in many cases) participate in the examination. They may be intubated, as you said, sedated or maybe even not sedated, and there's not necessarily much to follow on the exam to begin with if the GCS is very low. So, I'd love to hear your thoughts and your pearls, as someone who rounds in the neuro-ICU almost every day. What are you looking for at the bedside to try to detect sort of covert deterioration, if you will, in patients who already have major neurologic deficits, major neurologic injury or disease that we're aware of? I'm trying to see if there is some type of difference at the bedside that would lead you to be concerned for some underlying change and go back to the scanner or repeat EEG, LP, et cetera. Dr Wahlster: Yeah. I think that's an excellent question because that's a lot of what we do in the neuro ICU, right? And when you read your Clans, your residency, like, “Ah, QNR neuro checks, [IG1]  ” right? We often do that in many patients. But I think in the right patient, it can really be life or death a matter, and it is the exam that really then drives a whole cascade of changes in management and detects the need for lifesaving procedure. I would say it depends very much on the process and what you anticipate, right? If you have, for example, someone with a large ischemic stroke, large MCA stroke, especially, right, then there's sometimes conversations about doing a surgical procedure before they herniate. But let's say, kind of watch them and are worried that they will, you do worry about uncal herniation, and you pay attention to the pupil, because often, if the inferior division is infarcted, you know, you can see that kind of temporal tickling the uncus already. And so, I think those are patients that I torture with those NPi checks and checking the pupil very vigilantly. I would say, if it's a cerebellar stroke, for example, right, then you think about, you know, hydrocephalus. And often patients with cerebellar stroke - you know, the beauty of it is that if you detect it early, those patients can do so well, but they can die, and will die if they develop hydrocephalus start swelling. But I think, often something I always like to teach trainees is looking at the eye movements in upgaze and downgaze because, often, as the aqueduct, the third ventricle gets compressed and there's pressure on the colliculi – you kind of see vertical gaze get worse. But I would say I think it's always good to know what the process is and then what deterioration would look like. For example, in subarachnoid hemorrhage, where you talk about vasospasm - it's funny - I think a really good, experienced nurse is actually the best tool in this, but they will sometimes come to you and say, “I see this flavor,” and it's actually a constellation of symptoms, especially in the anterior ACA (ACom) aneurysms. You sometimes see patients suddenly, like, making funky jokes or saying really weird things. And then you see that in combination with, sometimes, a sodium drop, a little bit of subfebrile temperature; blood pressure shoot up sometimes, and that is a way the brain is sometimes regulating. But it's often a constellation of things, and I think it depends a little on the process that you're worried about. Dr Berkowitz: Yeah, that's very helpful. You just gave us some pearls for detecting deterioration related to vasospasm and subarachnoid hemorrhage; some pearls for detecting malignant edema in an MCA stroke or fourth ventricular compression in a large cerebellar stroke. Patients I find often very challenging to get a sense of what's going on and often get scanned over and over and back on EEG, not necessarily find something: patients with large intracerebral hemorrhage (particularly, in my experience, if the thalamus is involved) just can fluctuate a lot, and it's not clear to me actually what the fluctuation is. But you're looking for whether they're developing hydrocephalus from third ventricular compression with a thalamic hemorrhage (probably shouldn't be seizing from the thalamus, but if it's a large hemorrhage and cortical networks are disrupted and it's beyond sort of the subcortical gray matter, or has the hemorrhage expanded or ruptured it into the ventricular system?) And yet, you scan these patients over and over, sometimes, and just see it's the same thalamic hemorrhage and there's some, probably, just fluctuation level of arousal from the thalamic lesion. How do you, as someone who sees a lot of these patients, decide which patients with intracerebral hemorrhage - what are you looking for as far as deterioration? How do you decide who to keep scanning when you're seeing the same fluctuations? I find it so challenging - I'm curious to hear your perspective. Dr Wahlster: Yeah, no - that is a very tricky one. I mean, unfortunately, in patients with deeper hemorrhages or deeper lesions - you know, thalamic or then affecting brainstem - I think those are the ones that ultimately don't have good, consistent airway protection and do end up needing a trach, just because there's so much fluctuation. But I agree - it's so tricky, and I don't think I can give a perfect answer. I would say, a little bit I lean on the imaging. And for example - let's say there's a thalamic hemorrhage. We recently actually had a patient - I was on service last week - we had a thalamic hemorrhage with a fair amount of edema on it that was also kind of pressing on the aqueduct and didn't have a lot of IVH, right? But it was, like, from the outside pushing on it and where we ended up getting more scans. And I have to say, that patient actually just did fine and actually got the drain out and didn't need a shunt or anything, and actually never drained. We put an EVD and actually drained very little. So, I think we're still bad at gauging those. But I think, in general, my index of suspicion or threshold to scan would be lower if there was something, like, you know, a lot of IVH associated, if, you know, just kind of push on the aqueduct. It's very hard to say, I think. Sometimes, as you get to know your patients, you can get a little bit of a flavor of what is within normal fluctuation. I think it's probably true for every patient, right? - that there's always some fluctuation within the realm of like, “that's what he does,” and then there's something more profound. Yeah, sorry - I wish I could give a better answer, but I would say it's very tricky and requires experience and, ideally, you really taking the time to examine the patient yourself (ideally, several times). Sometimes, we see the patient - we get really worried. Or the typical thing we see the ICU is that the neurosurgeons walk around at 5 AM and say, like, “She's altered, she's different, she's changed.” And then the nurse will tell you at 8 AM, like, “No, they woke up and they ate their breakfast.” So, I think really working with your nurse and examining the patient yourself and just getting a flavor for what the realm of fluctuation is. Dr Berkowitz: Yeah - that's helpful to hear how challenging it is, even for a neurocritical care expert. I'm often taking care of these patients when they come out of the ICU and I'm thinking, “Am I scanning these patients too much?” Because I just don't sort of see the initial stage, and then, you know, you realize, “If I'm concerned and this is not fitting, then I should get a CT scan,” and sometimes you can't sort it out of the bedside. So, far from apologizing for your answer, it's reassuring, right, that sometimes you really can't tell at the bedside, as much as we value our exam. And the stakes are quite high if this patient's developed intraventricular hemorrhage or hydrocephalus, and these would change the management. Sometimes you have these patients the first few days in the ICU (for us, when they come out of the ICU) are getting scanned more often than you would like to. But then you get a sense of, “Oh, yeah - these times of day, they're hard to arouse,” or, “They're hard to arouse, but they are arousable this way,” and then, “When they are aroused, this is what they can do, and that's kind of what we saw yesterday.” And yet, as you said, if anyone on the team (the resident, the nurse, the student, our neurosurgery colleague) says, “I don't think this is how they were yesterday,” then, very low threshold to just go back and get a CT and make sure we're not missing something. Dr. Wahlster: Exactly. Yeah. I would say the other thing is also certain time intervals, right? If I'm seeing a patient that may be in vasospasm kind of around the days seven to ten, for the first fourteen day, I would be a little bit more nervous. Or with swelling - acute ischemic stroke says that could peak swelling, when knowing which [IG2]  , I would just be more anxious or have a lower threshold to scan. Yeah. Dr Berkowitz: Yeah - very helpful. Well, thank you so much for joining me today on Continuum Audio. Dr Wahlster: Thank you very much, Aaron. Dr Berkowitz: Again, today we've been interviewing Dr Sarah Wahlster, whose article, “Examination and Workup of the Neurocritical Care Patient” appears in the most recent issue of Continuum, on neurocritical care. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practice. And right now, during our Spring Special, all subscriptions are 15% off. Go to Continpub.com/Spring2024 or use the link in the episode notes to learn more and take advantage of this great discount. This offer ends June 30, 2024. AAN members: go to the link in the episode notes and complete the evaluation to get CME. Thank you for listening to Continuum Audio.

A unique coming of age story, Aggressive Optimism explores the complex landscape of mental health, the importance of solidarity, and the power of perseverance.'Nif is a talented singer trapped in a small hometown. Though she thrives in her choir, she longs for a life in Hollywood. After a breakthrough solo performance, her talents are recognized by a popular media personality and her hopes for her big break soar. Until a devastating accident derails her dreams and confronts her with new and unexpected challenges. With the help of her family and dear friends, Nif must reassemble the pieces of her life and discover a wellspring of inner strength. In the process, her aggressive optimism becomes a source of inspiration, not only for herself but for those around her.'Bio - Jenna EdwardsGrowing up in the middle of Minnesota's cornfields, Jenna had some big dreams. She wanted to make people laugh on TV, inspire change, and travel the world. Life wasn't easy, though. Born to teenage parents who split when she was three, Jenna faced poverty and abuse until her mom took a stand, and they escaped.In her early twenties, Jenna set off for Los Angeles, to make her dreams come true. She even landed a role on the legendary "Buffy the Vampire Slayer" show. Imagine inheriting Buffy's powers! But then, a terrible accident shook her world. She struggled with debilitating Post Traumatic Stress Disorder (PTSD) but learned that asking for help is a sign of strength, just like Buffy asking her friends for help.Websitewww.jennaedwards.comSocial Media InformationIG @jennaedwardsofficialResources MentionedBig Magic - Elizabeth GilbertShow Sponsor – National Association for Primary Education (NAPE) www.nape.org.ukSupport the show at www.educationonfire.com/supportHave you seen our live shows on YouTube? www.EducationOnFire.com/youtube

Наш ведущий Тимур спустя полгода жизни в Португалии наконец-то смог собрать себя в кучу и записать сумбурный выпуск про свою жизнь здесь. Если у вас есть предложения, вопросы или идея по поводу контента про жизнь в Португалии, то пишите нам на почту zavtracast@gmail.com. Подписывайтесь и ставьте лайк, а также не забудьте нажать на колокольчик на нашем ютубе – https://youtube.com/zavtracast    Если вы хотите нас поддержать из России, то подписывайтесь на нас на Boosty – https://boosty.to/zavtracast Если вы находитесь за границей, то можно подписаться на нас еще и на сервисе Patreon – https://patreon.com/zavtracast  Подписывайтесь на каналы ведущих в Телеграме: – Фотодушнила – https://t.me/dushovato – Сказки Дядюшки Зомбака – https://t.me/zombaktales В целом про выбор страны и какие у вас есть альтернативы, если вы хотите в Европу и не хотите зависеть от контракта (Португалия, Испания, Италия, Турция). Про цены в Португалии и как здесь существенно экономить без напряга. Как выбрать регион и город для проживания, а также какие могут быть особенности. Чем грозит жить на “отшибе Европы”. Сколько стоит обогреть квартиру электричеством и зачем нужны дегидраторы. Как получить визу Digital Nomad – читать гайды или обращаться к профессионалам (например, Татьяна – https://t.me/Tanchela_s) Почему нельзя забывать про всякие мелочи типа контрактов, NIF, NISS, Utente […] Запись Завтракаст – Portugal Special впервые появилась Zavtracast.

  Positron Range Correction PETHunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Hunor Kertesz about how he has implemented  Positron Range Correction PET with commercial PET scanners! This can make huge improvements in PET especially in cardiac and Gallium PET. TAGS PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Positron Range Correction PET Hunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Hunor Kertesz about how he has implemented  Positron Range Correction PET with commercial PET scanners! This can make huge improvements in PET especially in cardiac and Gallium PET. TAGS PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Positron Range Correction PETHunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Hunor Kertesz about how he has implemented  Positron Range Correction PET with commercial PET scanners! This can make huge improvements in PET especially in cardiac and Gallium PET. TAGS PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Positron Range Correction PET Hunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Hunor Kertesz about how he has implemented  Positron Range Correction PET with commercial PET scanners! This can make huge improvements in PET especially in cardiac and Gallium PET. TAGS PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Positron Range Correction PET Hunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} We talked to Hunor Kertesz about how he has implemented  Positron Range Correction PET with commercial PET scanners! This can make huge improvements in PET especially in cardiac and Gallium PET. TAGS PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

As private and government interest in nuclear fusion technology grows, an array of startups have arisen to take on the challenge, each with their own unique approach. Among them: LaserFusionX. Today on Faster, Please!—The Podcast, I talk with CEO Stephen Obenschain about the viability of fusion energy, and what sets his approach apart.Obenschain is the president of LaserFusionX. He was formerly head of the Plasma Physics Division branch at the U.S. Naval Research Laboratory.In This Episode* Viability of commercial fusion (0:58)* The LaserFusionX approach (7:54)* Funding the project (10:28)* The vision (12:52)Below is a lightly edited transcript of our conversationViability of commercial fusion (0:58)Pethokoukis: Steve, welcome to the podcast.Obenschain: Okay, I'm glad to talk with you. I understand you're very interested in high-tech future power sources, not so high tech right now are windmills…Well, I guess they're trying to make those more high tech, as well. I recall that when the Energy Department, the National Ignition Laboratory [NIF], they had the—I guess that's over about maybe 15 months ago—and they said they had achieved a net gain nuclear fusion, using lasers, and the energy secretary made an announcement and it was a big deal because we had never done that before by any means. But I remember very specifically people were saying, “Listen, it's a great achievement that we've done this, but using lasers is not a path to creating a commercial nuclear reactor.” I remember that seemed to be on the news all the time. But yet you are running a company that wants to use lasers to create a commercial fusion reactor. One, did I get that right, and what are you doing to get lasers to be able to do that?I don't know why people would come to that conclusion. I think we are competitive with the other approaches, which is magnetic fusion, where you use magnetic fields to confine a plasma and get to fusion temperatures. The federal government has supported laser fusion since about 1972, starting with the AEC [Atomic Energy Commission]. Originally it was an energy program, but it has migrated to being in support stockpiled stewardship because, with laser fusion, you can reach physics parameters similar to what occur in thermonuclear weapons.Yeah. So that facility is about nuclear weapons testing research, not creating a reactor—a fusion reactor.Yeah. All that being said, it does advance the physics of laser fusion energy, and what the National Ignition Facility did is got so-called ignition, where the fuel started a self-sustaining reaction where it was heating itself and increasing the amount of fusion energy. However, the gain was about three, and one of the reasons for that is they use so-called indirect drive, where the laser comes in, heats a small gold can, and the X-rays from that then that drive the pellet implosion, which means you lose about a factor of five in the efficiency. So it's limited gain you get that way.Your way is different. It sort of cuts out the middleman.Okay. The better way to go—which, we're not the only ones to do this—is direct drive, where the laser uniformly illuminates the target at the time that Livermore got started with indirect drive, we didn't have the technologies to uniformly illuminate a pellet. First at NRL [Naval Research Laboratories], and then later at University of Rochester in Japan, they developed techniques to uniformly illuminate the pellets. The second thing we're doing is using the argon fluoride laser. The argon fluoride laser has been used in lithography for many years because it's deep UV.The unique thing we have been trying to do—this was when I was supervising the program at the Naval Research Laboratory—was to take it up to high energy. We started years ago with a similar Krypton fluoride laser, built the largest operating target shooter with that technology, demonstrated the high repetition rate operation that you need for energy and NIF will shoot a few times a day—you need five to 10 shots per second to do a power plant—demonstrated that on a krypton fluoride laser, and, more recently, we switched to the focus to argon fluoride, which is deeper UV and more efficient than the Krypton  fluoride. And that basically—at NRL when I was supervising it—reached the energy record for that technology. But we've got a long ways to go to get it to the high energy needed for a power plant.Now, what the immediate goal of my company is to get the funds and to build a beam line of argon fluoride that would have the energy and performance needed for a power plant. One of the advantages to laser fusion: you want have a situation where I'm building more than one of something, so for an implosion facility, you have many beam lines, so you build one and then you have the advantage of building more, and a learning curve as you go toward a power plant. We developed a phase program where first we build the beamline, then we build a NIF-like implosion facility only operating with the argon fluoride, demonstrate the high gain—which is a hundred plus for a power plant—and then, after doing that, do the physics in parallel, develop the other technology you need, like low-cost targets. (They can't be expensive. The NIF targets are probably tens of thousands. We can't spend that.) We're going 10 shots per second. All the technologies required for a pilot power plant build a pilot power plant, which, in my view could be maybe 400 megawatts electricity. However, its main function would be to develop the procedures, test the components, and so forth for the follow-on, mass-produced power plants. So one, when you build a pilot power plant, you want to operate it for a few years to get the kinks out before going to mass production. The vision is to go from the beginning of that to the end in about 16 years.So the challenges are you have to generate enough heat, and you have to be able to do this over, and over, and over again.Right. That's right. It has to be high reliability. For an implosion facility, a hundred-thousand-shot reliability is okay. For a power plant, it's got to be in the billion-shot class.And at this point, the reason you think this is doable is what?I think we have confidence in the pellet designs. I have a lot, and I have colleagues that have a lot of experience with building large excimer systems: KrF [Krypton Fluoride Excimer Laser], ArF [Argon Fluoride Excimer Laser]…Those are lasers?Yes. And we have credible conceptual designs for the facility.There's a lot of companies right now, and startups, with different approaches. I would assume you think this is the most viable approach, or has some other advantages over some of the other things we're seeing with Commonwealth Fusion Systems, which gets mentioned a lot, which is using a different approach. So is the advantage you think it's easier to get to a reactor? What are the advantages of this path?The LaserFusionX approach (7:54)Well, for one, it's different. It's different challenges from the Commonwealth Fusion Systems. There is overlap, and there should be collaboration. For example, you have to, theirs is also deuterium-tritium. However, the physics challenges are different. I think we're farther along in laser fusion to be able—it's a simpler situation than you have. It's very complex interactions in tokamak, and you also have things… have you ever heard of a disruption? Basically it's where all of the magnetic energy all of a sudden goes to the wall, and if you have something like what Commonwealth Fusion Systems—they've got to be careful they don't get that. If they do, it would blow a hole in the wall. We don't have that problem with laser fusion. I think we're further along in understanding the physics. Actually, the National Ignition Facility is ahead of the highest fusion gains they've gotten in facilities. I think that they're somewhere just below one or so with the jet. They're up at one and a half. To what extent are the challenges of physics and science, and to what extent are the challenges engineering?Well, the physics has to guide the precision you have on the laser. And I won't say we're 100 percent done in the physics, but we're far enough along to say, okay. That's one reason where I envision building an implosion facility before the pilot power plant so we can test the codes and get all the kinks out of that. Nothing's easy. You have to get the cost of the targets down. The laser, okay, we've demonstrated, for example, at NRL—And NRL is…?Naval Research Laboratory.Naval Research Lab, right.A hundred-shot operation of the KrF laser. We use spark gap for that. We need to go to solid state pulse power, got up to 10 million shots. We need to get from there to a billion shots. And some of that is just simply improving the components. It's straightforward, but you've got to put time into it. I think you need really smart people doing this, that are creative—not too creative, but where you need to be creative, you are creative, and I think if, basically, if you can get the support, for example, to build (a beam line is somewhere around a hundred million dollars). To build the implosion facility and pilot power plant, you're getting into the billion shot, billion dollar class and you have to get those resources and be sure enough that, okay, if the investors put this money in, they're going to get a return on it.Funding the project (10:28)I think people who are investing in this sector, I would assume they may be more familiar with some of the other approaches, so what is the level of investor interest and what is the level of Department of Energy interest?Well, one of the challenges is that, historically, the Department of Energy has put money into two pots. One, laser fusion for stockpile stewardship, and magnetic fusion for energy. That's starting to change, but they don't have a lot of money involved yet, to put money into laser fusion or inertial fusion energy. And one of my challenges is not that the companies are aware of magnetic fusion, they don't understand the challenges of that, or laser fusion, or what's a good idea and a bad idea. And like Commonwealth Fusion systems I think has a good technical basis. If you go the next one down to Helion Energy, they're claiming they can burn helium three made from deuterium interactions, which violates textbook physics, so I'm very… I wonder about that.Would it surprise you, at the end of the day, that there are multiple paths to a commercial fusion reactor?Oh no. I think there are multiple paths to getting to where I get fusion burn, and maybe I make electricity. I think ultimately the real challenge for us is: Can we go reasonably fast? At 16 years, I'm considered somewhat slower than others. The ones that are saying five years I think are delusional. The ones that are saying 50 years, or say never, I don't think understand that yeah, we're pretty far along in this.How big, or rather, how small, theoretically, could one of these reactors be? I know there's been talk about using nuclear fusion as a way to provide power for these new data centers that gobble up so much power that they're using AI for. Would this be the kind of reactor that would power a city power, a big factory power, a data center, all of the above?I think you can get down, at least with our approach, to a couple hundred megawatts. However, my own vision is you're probably better off having power stations for some of the nuclear—with these, the big nuclear plants have multiple reactors at one place, and you'd get the advantage, for example, in our case, to just simply have one target factory and so forth. I don't think we're going to be able to compete. I don't know how small modular reactors go—a hundred megawatts or so, I would guess, and probably can't get down there, but one of my own goals is to get the size down as much as possible, but I think we're talking about hundreds of megawatts. The vision (12:52)What's the big vision? Why are you doing this?Why am I doing it?Yeah, what's the vision? What drives you and where do you think this goes over the next two decades?I may have the best route to get there. If I thought one of these other ones were going to get there, no problem… but all of us have challenges, and I think we can get there. I think from a standing start. As far as getting investment, I've just had pre-seed money, I don't have the big bucks yet. I've brought on people that are more experienced than me at extracting money from VCs and investors. (I was told you know a few billionaires.) Basically, for me, I need a few tens of millions to get started—like I'd say, about a hundred million to build the beamline. And then after that… actually I have a conference call on Friday with a representative of the investment bank industry that is very dubious about fusion.I mean, you can understand the skepticism, as a technology. What do they say? “It's the future of energy and always will be.”But the really good thing, I think, about the private investment is that the public investment has been too much focus on big machines which will give you physics, but have pretty much zero chance of being a direct path to fusion energy. You know, $25 billion and I make 500 megawatts thermal, occasionally, and we show that to a power plant executive, they're going to say, “You're kidding me.” We hope to get down cost for the power plants in the few-billion-dollar range.Faster, Please! is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit fasterplease.substack.com/subscribe

Please consider donating to our good friend Sue Lee Bun and help her fight Cancer. gofundme.com/teamsuebun https://venmo.com/u/Bun-TrailWelder The National Ignition Facility at Lorence Livermore Labs is where they cause the Big Bang. Jimmy and Tyler were lucky enough to be invited on a tour of the NIF. This is where they superheat small molecules and create fusion power. They learned so much about lasers and it made them feel like their lasers were very inadequate. Send us old license plates:SnailTrail4x4 / MORRFlate1065 National Dr, Suite 5, Sacramento, CA 95834 Want to win some Tires? Our friends at Yokohama are donating a set of tires for the 750 Apple Podcast reviews giveaway winner. Also, like before, we will give away swag packs every 50 until we get to the main giveaway. All reviews need to be left on Apple Podcast to be entered. Congratulations to TannerIsCooler for winning the 550 reviews swag pack. CALL US AND LEAVE US A VOICEMAIL!!!! We want to hear from you even more!!! You can call and say whatever you like! Ask a question, leave feedback, correct some information about welding, say how much you hate your Jeep, and wish you had a Toyota! We will air them all, live, on the podcast! +01-916-345-4744. If you have any negative feedback, you can call our negative feedback hotline, 408-800-5169. 4Wheel Underground has all the suspension parts you need to take your off-road rig from leaf springs to a performance suspension system. We just ordered our kits for Kermit and Samantha and are looking forward to getting them. The ordering process was quite simple and after answering the questionnaire to ensure we got the correct and best-fitting kits for our vehicles. If you want to level up your suspension game, check out 4Wheel Underground. Episode 477 is brought to you by all of our peeps over at patreon.com and irate4x4! Make sure to stop by and see all of the great perks you get for supporting SnailTrail4x4! Discount Codes, Monthly Give-Always, Gift Boxes, the SnailTrail4x4 Community, and the ST4x4 Treasure Hunt! Thank you to all of those who support us! We couldn't do it without you guys (and gals!)! Febuary's Giveaway is a set of 17" Coyote Inner Beadlocks. Inner Beadlocks are a fantastic way to make your wheels have the beadlock feature when you don't have beadlock wheels. It not only locks in the outer beadlock like everyone is used to but it also locks the inner bead as well. Jimmy runs a version of these on Bobcat and absolutely loves them. Massive thanks to MORRFlate for donating a full set of Coyote Inner Beadlocks for this months giveaway. If you're interested in winning this month's giveaway make sure you sign up on Irate4x4.com Snail Squad Membership. Congratulations to Sergio Rodriguez for winning January's Giveaway is with RollerCam. RollerCam makes quick and easy tie-down straps for everyday purposes. Their new patented design helps you sinch down the strap tightly and helps hold a tighter strength than traditional cam straps. Their new Rope Roller works with Paracord and allows you to tighten any situation quickly. If you need some tie-down straps make sure to sign up for the giveaway tier on Irate4x4.com Listener Discount Codes: SnailTrail4x4 -SnailTrail15 for 15% off SnailTrail4x4 MerchMORRFlate - snailtrail to get 10% off MORRFlate Multi Tire Inflation Deflation™ KitsIronman 4x4 - snailtrail20 to get 20% off all Ironman 4x4 branded equipment!Sidetracked Offroad - snailtrail4x4 (lowercase) to get 15% off lights and recovery gearSpartan Rope - snailtrail4x4 to get 10% off sitewideShock Surplus - SNAILTRAIL4x4 to get $25 off any order!Mob Armor - SNAILTRAIL4X4 for 15% offSummerShine Supply - ST4x4 for 10% off4WheelUnderground - snailtrail for 5% Midroll Music by ComaStudio

If hindsight is 20/20, then this podcast can help you forecast your future in a global lifestyle. Kristin shares 7 things she wishes she knew about living overseas before she moved abroad for the first time (back in 2002).    Check the show notes below for lots of great resources from this episode!    SPECIAL OFFERS:  Annual Feedback Survey (Win a Free Call with Kristin) Apply for moving overseas support Digital Nomads For Dummies book Get $10 off a NISS or NIF in Portugal with Bordr Portugal Trip Survey (Help Kristin plan a future group trip) Join Kristin's Newsletter   RELATED PODCASTS: Ep 212: 8 Ways to Overcome Reverse Culture Shock   RELATED VIDEOS: 7 Things to Know BEFORE You Move Abroad The Downsides of Living Abroad  What I Love About Living Abroad How I See the US After Living Abroad My Experience Living Japan as an Expat Living in the UK as an American (Culture Shock)   ADDITIONAL RESOURCES: tbd   Connect with Kristin and Support the Show: *   Become a Patron *   Buy a Coffee *   Follow on Instagram *   Join the Facebook Group *   Leave a 5-Star Review *   Subscribe on YouTube   See the show notes pages on BadassDigitalNomads.com or TravelingwithKristin.com/podcast  for time stamps, transcripts, and more resources from this episode.

What is nuclear fusion?Nuclear fusion produces energy by fusing atoms together. Atomic cores (nuclei) merge together to form a heavier—though unstable—nucleus, releasing mass to regain stability. This mass release corresponds to an energy release, given Einstein's equation E=mc2, which says in part that mass and energy can be converted into each other. The sun, along with all other stars, uses nuclear fusion to generate energy, which is released as heat and light. The 2022 Fusion Breakthrough In late 2022, scientists led by Dr. Annie Kritcher at the Lawrence Livermore National Laboratory (LLNL) briefly replicated the power of the sun. Replicating the sun's power requires replicating the extreme heat and density conditions within the sun's core. Atomic cores are positively charged, meaning they repel each other. To overcome this barrier, scientists need to apply massive amounts of heat and keep atomic cores extremely close together. For the first time, scientists produced more energy from fusion than the amount of energy it took to maintain these conditions. Fusion is a greenhouse-gas-free source of potentially unlimited electricity, powered by hydrogen we can take from water, and creating no long-lived radioactive waste. According to the International Atomic Energy Agency, fusion generates four times more energy per kilogram than the fission used for powering nuclear plants, and nearly 4 million times more energy than burning fossil fuels for energy. What's Next?Commercial nuclear fusion is still a long way off. While the physics aspect of fusion is “solved,” fusion remains a complicated engineering problem. The National Ignition Facility (NIF) at Lawrence Livermore National Laboratory has the most powerful laser in the world to blast heat at atoms, but it is the size of three football stadiums, very old, slow, inefficient, and clunky. There are still unanswered questions, such as how to affordably capture fusion energy, and how to keep a fusion reaction going for a long period of time. And although the laser shots at the NIF were weaker than its fusion output, the amount of energy drawn from the grid to create those lasers is 120 times more than the fusion output generated at LLNL. About Dr. Annie KritcherDr. Annie Kritcher is a nuclear engineer and physicist at the National Ignition Facility at Lawrence Livermore National Laboratory Weapons and Complex Integration's Design Physics Division. She led the recent nuclear fusion breakthrough at LLNL. In 2022, Kritcher was elected fellow of the American Physical Society. She earned her PhD at UC Berkeley. Further ReadingA shot for the ages: Fusion ignition breakthrough hailed as ‘one of the most impressive scientific feats of the 21st century' | Lawrence Livermore National LaboratoryUK Power Grid Could Have First Commercial Fusion Reactor By 2030sWorld's largest nuclear fusion reactor promises clean energy, but the challenges are huge - ABC NewsAnnie Kritcher leads revolutionary nuclear fusion experimentIAEA, What is nuclear fusion?NOVA Now Universe Revealed Podcast, Can We Recreate the Power of Stars Down on Earth? (YouTube or NOVA Podcast website) For a transcript, please visit https://climatebreak.org/the-clean-energy-potential-of-nuclear-fusion-with-annie-kritcher/

At this point in the game if you've been following this podcast within the past 2 years you know how high of a regard we hold Shaykh Hanif's pen! The South End raised lyricist has captured the ear of the streets since his release from prison a few years back and has hit the ground running–creating timeless music, along with his Feed The Family camp! The last time we spoke to 'Nif it was over a year ago on episode 135 and he's been growing his following and influence in a major way. Just after dropping his most recent album "Wilderness of North America", Shaykh Hanif visited Shade45's "Showoff Radio" w/ Statik Selektah & Termanology before making his way back home to our podcast for this conversation highlighting the body of work. Linking up with Westside Gunn, our guy OT The Real, and Benny The Butcher, it's safe to say "The Saudi Prince" is well on his way into the right rooms!Join Charlie MaSheen, Gina Rodriguez, & KASH this week as we talk to Hanif about his latest project, touch on the disaster going on in the Middle East from the perspective of a man of Islamic religion, breaking down the album "Wilderness of North America" and SO MUCH MORE!!! And in traditional fashion, Shaykh Hanif ended the conversation with a SENSATIONAL #RedCupsAndRap Freestyle which can be viewed on our YouTube Channel! TAP IN!!!BE SURE TO GO BUY/STREAM SHAYKH HANIF's ALBUM "Wilderness of North America" AVAILABLE ON ALL DSPs!!!CHECK OUT ALL OF OUR CONTENT:http://www.linktr.ee/CWTFBradio

When the Supreme Court overturned Roe v. Wade last year, it sent the issue of legalizing abortion back to the states. After the court's decision, Ohio enacted a near-total ban on abortion--which remained legal for a little over two months until a Hamilton County judge placed the law on hold due to a lawsuit from the ACLU and Planned Parenthood. Currently, abortion is legal in Ohio before 22 weeks of pregnancy. With Issue 1, abortion proponents hope to enshrine the right to abortion in the state's constitution.rnrnIf passed, Issue 1 would allow a patient to "make and carry out one's own reproductive decisions, including decisions about abortion, contraception, fertility treatment, miscarriage care, and continuing pregnancy." It would still allow the state to restrict abortion after fetal viability, except when "necessary to protect the pregnant patient's life or health. Opponents to Issue 1 argue the amendment would increase access to abortions, remove parental rights, allow gender affirming care for minors.

Innovator, storyteller, philanthropist, and impatient optimist, Mick Ebeling is a Muhammad Ali Humanitarian of the Year, Fortune “Top 50 World's Greatest Leaders” and a 2x TIME “Top 50 inventor”. He has sparked a movement of pragmatic, inspirational innovation as a career producer and filmmaker, and is now the founder and CEO of Not Impossible Labs. Mick has dedicated his life to tapping into the power of technology and story to help elevate our world. Join Mick as we discuss with him the road from film to foundation and the impact NIF aims to keep building for us all. 

En el episodio de hoy vamos a darle la bienvenida a una invitada muy querida: la profesora Maribel Jiménez Juárez de España. Hoy Maribel viene al podcast para hablarnos de los beneficios de viajar a España para hacer una inmersión en español.Temas que se mencionan en este episodio:Viajar a España baratoIr a España a estudiarViajar a España como estudiante Hacer una inmersión lingüística en españolViajar a España desde USA¡Descargá la transcripción de este episodio!Obtené ahora mismo la transcripción del episodio con fotos, un glosario y actividades de comprensión uniéndote a nuestro grupo de familia y amigos. Además, tendrás acceso a un episodio BONUS cada mes y muchos otros beneficios como clases conmigo. Unite a nuestra comunidad de Patreon y empezá a hablar español con confianza. Más información en este enlace. https://patreon.com/easyargentinespanish ¿Necesitás que te de una mano con tu español?Crear un Podcast es un laburo tremendo, es decir, me lleva mucho tiempo y dedicación. Si te unís a nuestra comunidad, nos ayudás a seguir motivados para crear más contenido. A cambio, yo también te doy una mano, es decir, te ayudo con tu español. Con tu colaboración accederás a contenido exclusivo para que hables español como un auténtico argentino. Más información en este enlace. https://patreon.com/easyargentinespanish Recursos que complementan este episodio:Datos de contacto de la profe Maribel: Instagram: @spanishconversationteacher Programa de inmersiónIf you've been feeling overwhelmed by fast paced Spanish speakers and you're finally ready to better understand spoken Spanish, then do yourself a favor and go to easyargentinespanish.com/video. I created this FREE 10-minute video lesson to make sure you know the 3 key features of Argentine pronunciation to better understand spoken Spanish. Support the showRECURSOS INDISPENSABLES PARA ESTUDIANTES DE ESPAÑOL Clase GRATIS de pronunciación rioplatense para entender mejor el español hablado. https://easyargentinespanish.com/video GUÍA GRATIS de Frases útiles que te ayudarán a hablar en español con confianza cuando converses con argentinos. Episodios BONUS, transcripciones, glosarios, actividades y clases conmigo, entre muchos otros beneficios: Más información en este enlace. Blog de Easy Argentine Spanish: easyargentinespanish.com/blog Ebook: Help! I Am Dating an Argentinian: The Ultimate Guide to Learn Argentine Spanish. #1 New Release on Amazon! APP de gramática VOS SOS app de Easy Argentine Spanish para practicar el uso del pronombre "vos" vs "tú".

I'm so happy to share this episode of the Blaxit Global podcast. In this episode, I reunite with Natalie Wester who was featured in the Condé Nast article I wrote, How to Retire in Portugal: A Complete Guide, and our popular Moving Abroad Over 50 panel on our YouTube channel.Natalie  Wester is a former second-grade teacher and National State Teacher of the Year who retired from teaching as a second career at 59. A radical reinventor, permission-giver, and storyteller, she encourages midlife women to give themselves permission to change the life they're living so they can live a life they love.By 60 she became a solo around-the-world traveler and recovering social media avoider. At 61, she launched The Hot Goddess blog for midlife women and started a "blackboard to bourbon" journey by developing a Midlife Reimagined Apprenticeship and becoming a whiskey distillery intern. At 62, she became an expat and now calls Lourinhã, Portugal home.Mentioned in the Episode:Follow Natalie on Instagram: https://www.instagram.com/retired_rewired_inspired Check out The Hot Goddess BlogWatch Natalie in our Moving Abroad Over 50 YouTube panel How to Retire in Portugal - Condé Nast Traveler $10 discount with Bordr on NIF & bank account - https://www.bordr.com/?via=blaxitglobalLearn European Portuguese: Try Portuguese with Carla - https://journey.portuguesewithcarla.com/offer-collab/?ref=18Transfer money using Wise - https://wise.prElder Millennial SpeaksAn uncensored show for people who crave authentic conversations about the bullsh*t...Listen on: Apple Podcasts SpotifyEnroll in the Blaxit Global Move Abroad CourseBe ready...so you don't have to get ready! Move to Portugal w/ Portugal the Place From D7 rentals to real estate purchases, Portugal the Place will guide you through the process. Start Abroad: Relocation Experts Personalized Relocation Services to Make Your International Move Smooth and Easy. Blaxit Global listeners receive 10% off Start Abroad services! Join aspiring Black expats, expats, and re-pats where you can build community, get resources and gain support along your journey abroad….You're invited to join Blaxit Global Passport. Join Blaxit Global Passport - https://blaxit-global-passport.mn.co/Support the showJoin Blaxit Global PassportSubscribe to Blaxit Global on YouTubeBlaxit Global Website: www.blaxitglobal.comSupport the show - www.ko-fi.com/blaxitglobal

Are you a big fan of "Blades of Glory"? If so, don't miss out on this podcast episode featuring Dave Krinsky, "Blades of Glory" writer.Show Notes:Dave on Emmys: https://taylorwilliamson.comDave's Wikipedia: https://www.instagram.com/taylorcomedy/Dave on IMDB: https://www.imdb.com/name/nm2743976/Michael's Online Screenwriting Course - https://michaeljamin.com/courseFree Screenwriting Lesson - https://michaeljamin.com/freeJoin My Watchlist - https://michaeljamin.com/watchlistAutomated Transcript:Dave Krinsky (00:00):It's so funny in animation because we would do like a big, you know, Hank football. We'd do a big football episode with a lot of people in the crowd, and James would be like, okay, this is really streaming the animators. We can't do another big one next week. So next week we'd go, look, this is a very simple episode. It mostly takes place in the house. It's a very personal story between Hank and Bobby. He's like, Ooh, that's gonna strain the animators. It's gonna require a lot of acting . Yeah. I'm like, ok. So wait, we can't do anything.Michael Jamin (00:25):You're listening to Screenwriters Need to Hear This with Michael, Janet.Michael Jamin (00:33):Hey everyone. Welcome back to Screenwriters. Need to hear this, the podcast. I got another amazing guest today. I'm here with my many, he's been my next guest, has been my boss on many occasions. He's been my friend on one occasion, . And he's . Here he is. Boy, this guy's got good credits. So this is Dave Krinsky and he's a feature writer, show creator. He ran King of the Hill for, what was it, eight years? Eight seasons weDave Krinsky (00:59):Ran. Yeah, I think maybe seven. I can never quite keep track.Michael Jamin (01:02):Felt like eight. Right? He was a show runner, king of Hill for, for many seasons, but a writer on, I think you wrote on every single season, didn't you?Dave Krinsky (01:08):Yeah, we came in right after the first season had just aired. Right. So they were still rewriting and posting season one and starting writing season two,Michael Jamin (01:18):Jump and right in. And then also, we're gonna talk about everything, but I wanna give you a proper introduction. We wrote, co-wrote with his partner, blades of Glory. They ran a, a show called Lopez, which i, I worked on for a little bit. CRO created Silicon Valley. I've heard of that show. Also the Good Family that was a b c animated show ran Bebes and Butthead for a while executive produced movie called Extract. What, what else, what else did you, you did a lot of stuff, man,Dave Krinsky (01:46):Lady Glory. Did you mention that? Wait,Michael Jamin (01:48):I thought I said that. Didn't I not sayDave Krinsky (01:49):That? Yeah, you did. I tuned you out, Don Point. I've learned to tune you out early, soMichael Jamin (01:53):, but man, oh man, I wa how, but you also said, when we were chatting before we started recording, that you did a lot of movie rewr. I didn't even know you guys did other movie rewrites.Dave Krinsky (02:03):Yeah. So when we first came out, this was back, you know, like nineties. You really had to decide where you were. A movie writer, a TV writer. The agents didn't even talk to each other. So we had come out with some movie scripts. We just thought that was sort of the easiest way to break in. Right. And we had ended up selling a couple, we sold one to Warner Brothers. It was they bought it for Chevy Chase. And yeah. Then we got firedMichael Jamin (02:26):And they didn't make up obviously causeDave Krinsky (02:28):They, they didn't make it. We got fired and they hired someone else to rewrite. And our agent goes, that's great news. And I'm like, how's that? Great news? They go, it's not dead. If they're hiring someone else to rewrite it. And it was kind of an a-list writer, then that means it's still alive. But it ended up not getting made, although it's sort of, Ben made a few times because it was a very broad idea about a guy who, you know how we only use 10% of our brain's potential, right. While these scientists developed this serum that unlocked the other 90% instead of being injected in a, you know, good upstanding citizen like Michael Jamin. And it gets in, injected in this doofus Chevy Chase who basically becomes this like throbbing organi organism. He's got 10 times the site and after the hearing 10 times the athletic ability. So he is trying to like, make money and become famous with it.Michael Jamin (03:09):But So he was attached before there was a director or No.Dave Krinsky (03:12):So there was never even a director manager. He was attached, like Chevy Chase had a deal at Warner Brothers and Warner was looking for movies for him. So this, and then those days they were buying spec scripts left and right. Right. So they bought that from us and we spent like a long time rewriting it.Michael Jamin (03:26):So he was giving you the notes on what he wanted?Dave Krinsky (03:29):No, we never even met with him. I think, you know, I don't even know if you ever heard of it, to be honest, it really wasn't those days, Uhhuh , if you wanted a Chevy reputation movie, you bought 10 or 12 scripts and you developed until you found one that you wanted to do and brought to him.Michael Jamin (03:41):So you were dealing with his development people.Dave Krinsky (03:43):We were just dealing with Warner Brothers, Warner Brothers, and the producer. So the way it worked back then, and maybe they still did now, but the spec script market isn't really strong anymore. You would go to your agent with a spec and they'd go, okay, we're gonna send it to X producer who has a deal at Paramount and y producer who has a good relationship with Warner Brothers. And we're gonna, they're gonna go to the studios all on the same weekend and let 'em know. They have to decide. And then hopefully you get at least two offers so that you're playing 'em against each other. And that particular, we only got one from Warner Brothers, so the producer on the project we never even met until Warner Brothers had bought it. So then the producer, and it's a weird deal because we actually had a better relationship with the execs at Warner Brothers than we did with the producer. Like, we like their nodes better. So it's a weird political dynamic that you had to deal with. But we ended up selling a couple of projects that way that didn't get made. But ultimately when Blades of Gloria got made, then it was a ton of rewrite work. Michael Jamin (04:42):And then, but this was, this was during King of the Hill.Dave Krinsky (04:45):Bla Glory was during King of the Hill. I mean, we were doing our movie stuff before King of the Hill started. And, and we started looking around, you know, we sold stuff, but we weren't, we were, John and I were still sharing an apartment in Burbank and I was driving a car with no air conditioning. And I looked over at some of my buddies like Bill Martin, who was like buying a house and buying a nice car. And those guys were all on tv. And John and I were like, well, maybe we should, I mean, we always wanted to do tv but our agents just you, no, you're movie writers. So we ended up writing some TV specs scripts and then ended up getting a job in tv. But, so we were writing specs scripts, we were get assignments occasionally, or we would pitch on something, but it wasn't until Bla Glory that really was like, oh, okay, now we're getting a ton of movie rewrite.Michael Jamin (05:29):And then how did you know Bill Martin? Would you go to, did you go to college with him?Dave Krinsky (05:31):Yeah, we went to college together. So it was weird. It was like, it was me, John Bill, Peyton Reid, who directed all the Aunt Man movies. This guy John Schultz, who directed like Mike. And it was like we all kind of moved out here at the same time to try to pursue the business.Michael Jamin (05:46):Wow. I didn't even know that. And then, well, so was your, when did you decide that you wanted to be a writer? Like in high school or something?Dave Krinsky (05:53):Pretty much, I mean, I, I, this is make me sound really cool but I loved reading as a kid. I loved, you know, books. And I just loved when a story really impacted me and made me think. I was like, wow, that's a cool sort of power to have over people, to influence 'em that way. So since the time I was like 12, 13, I thought about it. And then in high school we had to write a short story for an English class. And I wrote this kind of science fiction funny story, and the teacher, you know, wrote a plus, what are you gonna do with this gift? And I was like, oh, I guess it actually could be a job. Right. So,Michael Jamin (06:24):But you think that it could be a job? Like I didn't, that didn't occur to me until I was older that you could make money in tv.Dave Krinsky (06:29):. Well, you know what I was thinking I'd be a book writer and so I went to Carolina cause I knew they had a strong English department. I took all the creative writing classes there. And since I didn't wanna really do anything else, I took whatever course I find. So screenwriting was one. Playwriting was one. And after I met John Alsk and my partner and, and David Palmer, who I worked with out here a bit.Michael Jamin (06:50):Wow. You were serious about it. Did you have to apply to those programs?Dave Krinsky (06:53):You know? Yeah, no, I mean, I, I was in the, I got accepted to the honors program, which was what I had applied for. And because of that I got to get into some of the writing classes I wouldn't have had access to anyway.Michael Jamin (07:05):So this is all or nothing for you? I mean, you, I mean, there was no plan BDave Krinsky (07:09):Well I, you know, my mom was always like, Ryan, you go to law school, you have something to fall back on. But I knew if I something to fall back and I'd probably fall back on it, you know? And, and it took us a while to get su you know, really established with Point. I could get rid of that crappy car with the o ac ac in the apartment with the oac. But if I had had the ability or the degree to do anything else, I probably would've bailed on the writing dream earlier.Michael Jamin (07:32):Right. Wow. And then, and then, so eventually you just had to move into tv and then how, I know, how did you get your first gig?Dave Krinsky (07:40):So we decided to move tv. We wrote a couple of spec scripts and I think it was Bill Martin who said, oh, you should meet Carolyn Strauss over at hbo o And Carolyn of course was, you know, at the vanguard of starting H B O when it was, yeah.Michael Jamin (07:54):Wait, he's setting up meetings for you? Like, he's like your agent now, bill? No,Dave Krinsky (07:57):It really was one of those things where it was like, we're like, Hey, we wanna get into TV doing, he goes, oh, well you should meet Ke Strauss. We like Hershey's really cool. And I think he might have told her, oh, you should meet these guys. Okay. And so we had a general with her and which was a good lesson. It was like, you know, I think we always had something to pitch. We always knew a general, everybody, you know, wants something. I can't remember if we pitched anything too specifically or not. Cuz in movies you always want to pitch an idea. Sometimes in TV it really is just a general Yeah. To see what you know. But, you know, it was a great meeting and nothing came of it. And then like nine months later we got a call from her and she goes, look, we're doing a show.(08:32): The showrunner really wants movie guys doesn't want like, just TV sitcom guys. Wow. And I thought of you guys, you, you look, look at the pilot, they shot a pilot and they sent the pilot over. It was a black and white period single camera show. David Ledon was the executive producer. Adam Resnick was the showrunner, the creator. And it was awesome. It was like the Cohen Brothers really dark funny. And we were like, yeah. So she set up a call with us. We talked to Adam for like an hour and a half, mostly about Goodfellas and the Godfather and just movies. And then they called us up, goes, look, will you the show's in New York, will you move there? And we're like, yeah, we'll move there. She goes, okay, three or four days, can you move? And we're like, yeah, what do we don't have? I don't even think we had a plant in our place, you know, our fresh food. So we moved toMichael Jamin (09:18):New York. And you got outta your rent You? Or do youDave Krinsky (09:20):Remember? We sublet Cause it was a, I think it was a 10 episode order that became an eight episode order, which is now, you know, the norm. But then was like, okay, so we're only gonna be there probably nine months of production. So we figured why give up our place.Michael Jamin (09:34):Do you think if it wasn't a good show, you would've taken, if it was a bad show, you would've taken the author?Dave Krinsky (09:40):Oh, that's a good question. You know, probably not, you know, before this happened, we were in the movie biz. We, we had a meeting with Polly Shore, right. And Polly was manager was in the meeting and his manager was a gentleman named Michael Rotenberg, who is now my manager. And, and Michael and and Sea have, you know, allMichael Jamin (09:59):Times he's our dealt withDave Krinsky (10:00):Them. He was an executor on King of the Hill. So this was before King of the Hill even. And we pitched Polly the new line, wanted to do a movie where Pauly basically, they sound of mu they wanted him to be a nanny. And we pitched like Sound of Music with Polly going around Europe and Polly was as insulting and, and, and just not a good collaborate. He was just say, Hey, who are these greasy weasels? And you know, he just goes, no, just turn the camera on and I'll be funny. And we're like, okay. But John I think had like $93 in this bank account and I might have had a little bit more. And they offered it to us and we were like, this could be our career right. Path that we don't want to be on. And we turned it down. So I think if it was a crappy show, we probably would've turned it down too.Michael Jamin (10:45):Right. Wow. You turned it down. Cuz I, you know, now you, I think now you take anything you forgetDave Krinsky (10:50):. Yeah, well certainlyMichael Jamin (10:51):It's not you, but one, one does. Right.Dave Krinsky (10:53):And it's not a bad, it's not bad advice. You gotta get in the game, you know? So we had already been in the game just enough that it wasn't like we were completely unknown. We had anything produced, so we certainly weren't a hot commodity. Right. But we really felt like, oh, this could just pigeonhole us. And it was interesting because our agent was like, okay, if you don't wanna do it, fine, but we don't really want to be rude and turn it down, so we're gonna ask for way more money than they'll ever pay you. Right. So they went and asked for like $400,000 and they were furious anyway. They're like, who the hell do you think you are asking anymore? It's just like, sorry, we just don't wanna do it. So. Right.Michael Jamin (11:31):How funny, did you, were you, when you first got on King of the, or I guess not, well I guess, you know, on Resnick's show, were you, did you, did you find it over? You were in over your head? I mean, that's how I felt when we started.Dave Krinsky (11:42):Oh yeah. Because I was always that one of those writers, and I'm sure there's plenty like that. I'm like, I don't even in college where you had to like, give your scr your scripts or your stories to people to read. I'm like, I don't wanna do this. You know? Cause I just didn't have the confidence or faith in myself. So we got to New York and we were working at a Letterman's theater. And Adam's great. I mean, he is the nicest guy. He's a super small staff. There's this John and I, this other team and this guy Vince Calandra. Right. And I just remember like sitting in the writer's room, not saying a word because I was like, I don't wanna say the wrong thing and look like an idiot. And, and in all honesty, when I got to King of the Hill, I looked around, I was like, I recognize names from seeing him on The Simpsons and you know, my judge of course. And I was inhibited there too. And I barely pitched, I think for the first couple of months I was there.Michael Jamin (12:30):Really. And then what was the moment when you felt like you could, you could test the waters?Dave Krinsky (12:36):Well, what happened was, I was just hanging out enough, like, so in the lunchroom, you know, I got to be friendly with people and people go out for a drink and then it suddenly was a social thing. And I was comfortable in that and I could start being funny that way. So by the time I got back to the room after a couple of months, it was kind of like, oh, I was just bull bullshitting with my friends, you know? And it was much easier to pitch because Right. It felt safer,Michael Jamin (13:00):Felt sa because I even remember on Kingley we had some interns, people would sit in pitching and I'm like, how did they get over their fear of pitching when they haven't been hired as a writer? .Dave Krinsky (13:10):Yeah. I mean, and it, it's a good question for young writers and, and I'm teaching a class down at Chapman now and, and I'm like, it's a tricky situation when you're a new writer, you want to talk cuz you want to prove you're mm-hmm. worthy. But if you talk too much or talk poorly Yeah. It doesn't do you any good. And it really, in my opinion, when as a showrunner, I would rather you be quiet and sort of take it all in and pitch very occasionally, then feel like you've gotta pitch stuff that ends up derailing the room.Michael Jamin (13:40):You know, I, I totally agree with you. The one thing I've said, cause I think a new, let's say there's 10 writers in a room, and a staff writer often thinks, well I better speak a 10th of the time because I'm, there's 10 people here, but they're not getting paid a 10th. They're not getting paid as much as the co-executive producer. They don't have to contribute as much. You know?Dave Krinsky (13:56):Yeah. And it's not expected. Like, I've seen plenty of horrible showrunners who are punitive and, you know, they don't make it easy for a staff writer and they're happy to fire a staff writer every season and try someone else. But John, I have always been like, look, we're gonna bring you on board. We're gonna be patient with you. You know, it's like, it's not an easy position to be in. And, and when you're a showrunner, all you want is someone to make your life easier. And if a staff writer makes your life easier one time in a season, it's almost like, okay, you know what? I got something outta you. Great. WhatMichael Jamin (14:27):About that leap from, cuz I was there for that. You were, I guess it was season 60 started running it, is that right?Dave Krinsky (14:35):Yeah, six seven was our first official year running here. Billy,Michael Jamin (14:38):What was it like for you making the le because you know, everyone, you always think, I could do this job, I could do the job better than my boss. And then you become the boss and you're like, wait a minute, this is hard.Dave Krinsky (14:47):Yeah. Well I remember when on that Resnik show, there was a consultant there, and he told us, he goes, the punishment for writing well is producing. And it's like, you know, you work your way up and you become a producer and suddenly Yeah. You're managing people, you're dealing with all the politics, the budget. And I think the, the biggest thing that happened to me was we were working, and I can't remember if you were in the room or not. Do you remember Collier's episode about that Michael Keaton did? What The Pig the Pigs are? Yeah.Michael Jamin (15:15):I was there for probably, we probably got there for the animatic part of it. So we were didn't great itDave Krinsky (15:20):Okay. So it was a really weird story and Collier's a great writer, but this was one that was trouble from the get go just because it was so bizarre. Yes. And and I remember we were working super late trying to get to it and, and I think Richard Chappelle was running the, the show at that point. And he and Greg were developing a show and they left the room and everybody left the room. There was like four of us in there, and I think Greg or Rich Dave, you get on the computer and I and King of the Hill, the room, it wasn't like a conference room, it was like a big, almost like living room with a Yeah. Scattered room. One person sat there, it kind of ran the room. We didn't have the screen showing the script, which I never liked anyway. And I was like, I don't think I can run a room. Mm-Hmm. . And I got up there and I was just like, you know, I just did what I had to do. And I remember we, you know, spent a few hours, it was late night and we kind of like gave the script rich and Greg, and they came and got, this is great, this is working. And it was like, oh gee, so I guess I can do it. Right.Dave Krinsky (16:15):So when we took over the show, yeah. I mean it definitely was like, you, so many things were harder than you would think, but some were easier too. I remember the other showrunners before we run the show would come back from pitching the story. So the network, and they go, well, we sold six outta seven of 'em. So, you know, it wasn't easy. And then when we started pitching to the network, you know, the show had been on for six, seven years. They were like, okay, good. It was like, oh, this isn't that hard. Right. The hard parts were, you know, managing the budget, managing people, managing writers, dealing with the network.Michael Jamin (16:47):How much budget were you dealing with? Like, what were you, how big was it? Like, were you what? No, I mean, like what, what exactly were you doing? You know? Oh, yeah, because I, I don't really touch the, when we were running stuff, we don't really touch the budgets, butDave Krinsky (16:58):What do you, oh, so I mean, first it was the writer's budget, which every year was like, yeah, okay. Like, who can we afford to pay? But I mean, a lot of it, you'll remember our, our line producer McKinsey would walk in and be like, you know what? Last episode had a football crowd and this episode you want to do, you know, whatever a a crowd scene at the school, we can't afford that. The budget won't. Right. You know, so a lot of it was making creative decisions based on the limitations. Although it's so funny in animation because we would do like a big, you know, Hank football, we do a big football episode with a lot of people in the crowd and Jims like, okay, this is really streaming the animators. We can't do another big one next week. So next week we'd go, look, this is a very simple episode. It mostly takes place in the house. It's a very personal story between Hank and Bobby. And he's like, Ooh, that's gonna strain the animators. It's gonna require a lot of acting . Yeah. Like, ok, so wait, we can't do anythingMichael Jamin (17:52):. There's always a reason. That's right. There's always a reason why you're gonna ruin the show,Dave Krinsky (17:57):The bank.Michael Jamin (17:58):Wow. That's so, and now and then so what ha, so then after King of the Hill, which you guys did for many years, then it went down and they then went down for, I was probably a couple years it went down. Right.Dave Krinsky (18:10):I don't remember if it was a couple years because Yeah. So the show did not get picked up. Right. And then they moved John and I and Clarissa assistant onto the lot, into this crummy little office to finish posting the shows. Right. And so we were there posting the shows and we never left. I mean, by the time we, we, it's not like we were like home and done before we left there. They, they picked the show up again for another run.Michael Jamin (18:38):What was the thinking behind canceling and then picking it up again? Like why?Dave Krinsky (18:42):From what I hear Uhhuh, it's so, you know, Fox Network ran the show. Mm-Hmm. , 20th Century Fox was the studio who owned the show. Right. And apparently the, the heads of the studio got big bonuses when they got new shows on the air that were successful. So they weren't making a ton of money.Michael Jamin (19:05):Personally.Dave Krinsky (19:06):Personally. And the other thing, apparently they owned and operated cuz everything was syndicated. You know, in those days the package was so high for them to pay. As the show got on that they were like, wow, we gotta renegotiate this deal. So when everybody started renegotiating, it seemed like, okay, let's not do it. And then ultimately, I bet it was Aria Emmanuel fought for, cuz he was always fighting for it. But, or maybe it was Rotenberg, but yes, that's whatever they just decided. Okay. They made a deal and picked us back up again.Michael Jamin (19:34):And at that point it was, it was a lot of new writers, well most of the writers had moved on, but you were still on the show. So the cause you kind of restarted the staff was almost, as I remember it was almost almost brand new. There was only a couple pre previous writers, like Christie Stratton was there,Dave Krinsky (19:51):I think Christie was there, kit was there, kit Balls, GarlandMichael Jamin (19:54):Garland was there. Sure. Okay.Dave Krinsky (19:56):Yeah. So there was definitely a core group. I remember like, I can't remember Tony and Becky came on. Right. I don't remember if that was before that or not. So I think enough people, it might have been like, nowadays there's not really a staffing season, but I think it might have been during a non-st staffing season that enough people hadn't landed somewhere that we could get, get him back.Michael Jamin (20:15):Right, right. And then after that, you guys did The Good Family?Dave Krinsky (20:20):Yeah. So that was another, you know, people wanted an animated show from us. We had, you know, we'd gotten very close to Mike on King of the Hill. So started working together a lot with him. And we had this, this show The Good Family about a very you know, PC family, sort of the opposite of Hank Hill. And I just remember, you know, everybody was like, okay, take it to Fox and it'll run for forever. And it was just like, we just wanted to do things differently. And m r c and Independent, you know, studio had came out, came after us pretty hard and said, no, we want to do this deal. We can finance it and, and you can have a better upside and more freedom and Okay. So we decided to do it and we pitched it around and a B C just made such a hard press for it.Michael Jamin (21:03):OhDave Krinsky (21:03):Wow. And yeah. And it turns out they weren't the best partners simply because they didn't have any animation on. Right. They put us on with a really bad animated show, like after Wipe Out or something. It was just like not a good fit. Right. So, but it ends up, you know, the bottom fell outta the industry right after that cuz Rotenberg would call us up and goes, you know, your numbers would be a top 10 show like within two years. Right. We would've been like, fine. But at that moment just wasn't good enough numbers.Michael Jamin (21:30):And then, and then came, then they brought back Beavis and Butthead, which you guys ran, which was so interesting cuz that was a whole different experience that, that was all freelance. That's why you guys called us, Hey, you wanna write a briefs and Butthead? We're like, yeah, we'll do that.Dave Krinsky (21:43):Yeah. I mean, who wouldn't wanna have an opportunity do that? Right. Yeah. So Mike, they've always begging Mike to bring it back and he was always like, yeah, the situation has to be right. And he just felt like the timing was right. And he had some stories he wanted to tell and he loves doing them. I mean Yeah. You know, as he always said, king of the Hill requires a ton of effort for a little bit of output. Bvis requires a little bit of input for a ton of output. You know, people just love it and it's funny. Yeah. so yeah, so I mean, the budgets weren't super high and we couldn't license music anymore. I mean, and when Mike originally did it, it was all music videos because M T V owned all those videos. Right. But the world had changed so suddenly we were doing Jersey Shore and, and a lot of other like, reality shows. Cause that was the only sort of material we could get mm-hmm. . Michael Jamin (22:29):Yeah. But we, that's, we did like, because I remember we brought, you guys brought us in, there's a, there was a woman, a couple women in Detroit, it was so cold in the deed, had a song so cold in the deed. ColdDave Krinsky (22:40):In the de Yeah.Michael Jamin (22:41):And I don't remember how it happened, but I, I think I commented on on her, maybe on her YouTube channel or something. I go, this is a great song. And she went with nuts. She's like, oh, thank you so much, . She's, so, yeah,Dave Krinsky (22:53):It was a weird sort of viral head, I think almost before things really went viral. And it was just like a homemade video about, you know, living in Detroit and Michael Jamin (23:01):And how did you find all that stuff?Dave Krinsky (23:03):Mike had found it and just thought it was really funny and really interesting. And soMichael Jamin (23:06):He was just surfing the internet looking for like, real cheap stuff that he could get.Dave Krinsky (23:11):I don't even think it was like with an eye toward Bes, but he also was in this little network of like, Knoxville and Spike Jones. They all like send each other stuff. So I don't know where he got it from, but I think he just saw it. And, and, and you know what, I, I don't know, he's never said, but that might have been. But just to bring Bes back where he is just like, oh my God, they'd have so much fun with this.Michael Jamin (23:30):Hey, it's Michael Jamin. If you like my videos and you want me to email them to you for free, join my watch list. Every Friday I send out my top three videos. These are for writers, actors, creative types. You can unsubscribe whenever you want. I'm not gonna spam you and it's absolutely free. Just go to michaeljamin.com/watchlistMichael Jamin (23:54):And then okay. So then what, what came after that?Dave Krinsky (23:58):So yeah, blades of Glory was in the middle of the King of the Hill era. Right. and then I guess Silicon Valley really would be the, the next big thing that,Michael Jamin (24:10):And Okay. How did you guys come up with that idea? Which is a pretty big hit.Dave Krinsky (24:15):Yeah. So that was an interesting confluence of events where Mike had been in talks with H B O, they really wanted to do something with him. And Scott Rudin wanted to do something in sort of the gaming space. Mm-Hmm. . So they were sort of circling around this tech world. And Mike's like, I'm not a gamer. I don't know that well, but Mike was an engineer, you know, electrical engineer, so he knew, you know that world well. Yeah. but John was reading the, the Steve Jobs book by Walter Isaacson and saw this quote in the book where it's like Bill Gates was making fun of Steve Jobs goes, he can't even code.Michael Jamin (24:48):Yeah.Dave Krinsky (24:49):So John had this idea. He goes, well that's a really funny world. And his, his brother was an electric engineer, so he knew that world as well. And you know, so we pitched an idea to Mike doing something that Mike goes, well, I would love to do that. So then when we pitched it to H B O, they were like, yeah, this sounds great.Michael Jamin (25:04):Sorry. Right. So you wrote the pilot shot it and you were, and then like what people don't understand is like the process for shooting a pilot or, you know, like it's a big deal. It's like a lot of work. It's like even casting is a lot of work.Dave Krinsky (25:18):Yeah. And it, it was a lot of work and, and you know, there's a lot of round, I mean, after to, you know, really it was pretty high on it even after our first draft. It felt like it was gonna move in the right direction. And I do remember them calling him saying, okay, we wanna shoot a pilot mm-hmm. . and we had just done a show for Nat Geo before this where the budgets, the budgets were, you know, very low. I can't remember what they were, but, so HBO calls saying, you know, look, the pilot's gotta, the budget's gotta have like a four or five in front of it and we're like 400, 500 grands ton, but we can probably do it. It was like, no, no, no. Four or 5 million, million(25:52):. And they, they actually forced us to go up to Silicon Valley to shoot for a few days, bring the whole company up and we're like, there's nothing up there. We can shoot this in la. You know, and we ended up shooting like on the side of a freeway and we had a couple establishing shots of Google and Facebook and Right. And stuff. But, you know, HBO does things and they want it to be authentic so you know, all the credit in the world to them. Right. and then, yeah. Then when we did an edit, it was interesting cuz the pilot to Silicon Valley has a very big subplot of these two women in LA who are tired of the LA scene and they go up to Silicon Valley cuz the guys are rich and nice and and nerdy. And they meet our heroes in the first episode. And h HP was like, yeah, you know, we don't want this storyline. We don't think we need it. So those poor actresses got cut outMichael Jamin (26:37):Mm-Hmm.Dave Krinsky (26:37): and yeah. Crushing. Crushing. Yeah. It's gotta be, gotta be tough to see a show be that and you're,Michael Jamin (26:44):And you were cut out of it. Yeah. Yeah. What now when you, I know you, you teach at Chapman, it's so interesting cuz some people are like, is film school worth it? It's like, it depends on who you get as your teacher. Like, honestly, it's like it, you know and I'm sure they're very lucky to have you. What do you, you know, what is it, what's it like with these kids? You know, what are you teaching them? What are, where are they coming from, I guess?Dave Krinsky (27:06):Yeah, so the class is writing for adult animation. So, you know, half hour animation was like King of the Hill and, and, and things like that. But you know, as you well know, writing for animation is very similar to writing for anything. You know, it, it really is. You still need your three x structure and everything you can just go a little crazier with with things. And yeah, I asked them all, you know, beginning, because it, a lot of people still ask me, is it worth going to film school? Look, film school's expensive if you can afford it. Mm-Hmm. , it's not a bad thing. And I think what these kids are getting, and I said kids, but a lot of 'em are in their twenties. I think one's in his thirties, Uhhuh, . They're writing constantly. Someone's making to, that's good.(27:45):They're in LA so they're exposed to people, you know, not Pam or something, but like me who have done it in the business. We're not just academics who have published books about things. You know, and, and you know, you know, Brian Behar is down there, there's a bunch of Jill Con, there's a bunch of people down there who are like, done stuff. And last week or the other day, Damon, the guy who did La La Land, I can never say his last name in Whiplash. Yeah. He was speaking tonight. Austin Butler's speaking. Like, they just have a ton of people coming through. So you have exposure to all these people who have done things. Yeah. You also have connections that, you know, if you don't go to film till you just have to move to LA and try to, you know, try to build yourself. So yeah. So I think it's a, it's a good thing if you can afford it. If you can't afford it, it is not, it is not worth stretching to do it because, you know, we moved to LA and we started networking and meeting people and kept writing and, you know, that's really how most people do it. DoMichael Jamin (28:40):You feel you have to beat misconceptions out of them? You know,Dave Krinsky (28:45):I think this is my first class and I'm teaching second year grad students. Mm-Hmm. , so they're fairly savvy.Michael Jamin (28:53):Okay.Dave Krinsky (28:54):I think they've been exposed to it enough that there's not a ton of misconceptions, but there are big gaps in their knowledge. Just, you know, as it would be with anybody who, who hasn't been in the business. So, look, I teach them things about structure. Things like things they've probably heard before, but in ways that, you know, I, here's mistakes I've made before. You know, having a scene have to carry double duty and a half hour show is really difficult cause you have to change gears within the middle of a scene. You know, keep it simple. So things like that, I should, but they definitely light up more to my more anecdotal stories. Like, what's it like to be in the room? What's it like to work for a showrunner who's, you know, marginalizing you. What I remember I talked to the other day, I go, yeah, so we have this if come deal. And I could say, I go, wait, do you guys know what NIF come deal is? And they're like, no. I was like, oh, okay. Well let me explain that. So Right.Michael Jamin (29:45):What do you tell 'em about the showrunners? Who, who, who marginalized you? What's your, what's your advice on that? I wanna hear it.Dave Krinsky (29:51):Yeah, you know, it's just tough. I mean, I just keep stressing to them that most showrunners are under so much pressure and stress. All they want is someone to make their life easier. Mm-Hmm. . So, you know, the better you can do that, you know, the better off you'll be. And sometimes it's uncomfortable, but you need, like you, well I guess you weren't there at the beginning, but the king of the hill, you know, Greg was running the show and he had so many things you were on, so he was barely in the room. Right. So you didn't really know what he wanted. You didn't know if your story was gonna work. So if you saw em in the break room or saw em in the hallway, you would be like, Hey Greg, this is what we're doing. You know, you try to get feedback from em.(30:31):So that's what I tell them. I go do get as much from the showrunner as you can. And some of them won't give you anything as they're not rooting for you to succeed, but get as much as you can from them when you can, because it doesn't do you any good to try to figure out what they're doing. I mean, you have to do that to some level. The more you know what they want. And that's why I tell these, you know, these kids are doing beat sheets and outlines. I'm like, be as specific as you can. Don't cheat yourself because I'm gonna read stuff you gloss over and go, oh, I guess they know what they're doing. Right. And then when you gimme a script and I'm like, wait, what if you had done that in your outline? I could have pointed it out at that stage.Michael Jamin (31:06):Right, exactly. And when you say, cause when you say you know, you just helped the showrunner out, like, to me, what I want as a showrunner, what I, I just want a draft that doesn't need a page one rewrite. That's how I feel. I mean, is that what you're talking about?Dave Krinsky (31:20):Pretty much, yeah. I mean, or look, if you're someone who can, who can, you know, have the joke or the story fix in the room that gets you all home sooner, then that's fine too. I mean, you know, I mean, at King of the Hill we had such a big staff, it's an animated show. There were people who turned in great drafts. There were people who weren't great draft fighters, where were great in the room. You know, so in those days you could build a big enough team that, you know, you could have a pinch hitter and a utility field or designated here. Now the staff are so small, you really do want someone, but you're right. I mean, to get that draft mm-hmm. that needs a ton of work, you're like, okay, this sets us back so much on everything else now we can't, now I can't be in the editing room now. We can't push that next week's story forward. It's like, now we gotta dig in on this one.Michael Jamin (32:03):And, and what, what is, I mean that's exactly, yeah, that's exactly the panic that I, I I used to feel. But what did you, what is the advice, like, cause the industry's really changing so fast now. Like what is the advice you give these kids get out of film school in order to get into the business?Dave Krinsky (32:20):Yeah. I te look, it's tough. You know, I always try not to be too negative about it because it's always been tough. It's just tough in a different way. Right. you know what I tell them is like, look, the movie business is extraordinarily difficult. Mm-Hmm. . So if you want to be a movie writer, that's fine. But, you know, I urge them like, TV seems to be a cleaner path. Yeah. It used to be with movies, at least you could write a spec at some control where TV had to hope somebody hired you. So now, you know, I say, look, if you have a good movie idea, think about it as a series because, you know, a-list actors are all doing tv. You know, there's a, there's, and obviously TV is in a, isn't a great state right now with just the quality of it. Yeah. but yeah, I mean, you really do just have to, the basics are right, right, right. Mm-Hmm. and network, you gotta be in LA you gotta be hitting all the places because you never know. Look, that meeting with Carolyn Strauss, we had like, it was a good meeting. It wasn't like, ah, we've made it, we've met Carolyn Strauss and it wasn't until nine months later that something on the game of it. Right.Michael Jamin (33:19):Right. So it's really about getting in those circles.Dave Krinsky (33:21):Yeah.Michael Jamin (33:22):Yeah. I mean I, yeah, I remember people say that all times. Do I have to be in la? I'm like, you don't have to do anything you don't want, but you know, this is where the fish swim. You know?Dave Krinsky (33:32):Yeah. I mean the, the thing is, and I think you've probably said for, it's like the material doesn't really speak for itself. Mm-Hmm. , like in movies, it used to like a good specs script would find, you know, a, a buyer mm-hmm. , you know, now there's very few ideas that someone's gonna go, well, I don't care who this comes from, I want to do it. You know, and there's, there's very few scripts that are good enough that any anybody's gonna be like, I'm gonna put this on the air. It happens. They are out there. But the vast majority of the time it's, I've been hanging out, I've been going to, you know, upright citizens for grade. I've been going, oh, I've been helping out on a student film. Right. Hey, that kid I helped out is now on the desk at uta. Does UTA even exists anymore? I don't know. You know, myMichael Jamin (34:15):Agent? Yeah. I'm not sure.Dave Krinsky (34:15):Yeah. It's c aa and it's like, you know what, he wants to be an agent, so he's trying to hustle. So he's gonna hand the script over to, and suddenly you have a meeting, you know, with an agent, a real agent. So that's how it mo mostly happens. And you gotta be in LA for that.Michael Jamin (34:30):Yeah, exactly. That's how I feel.Dave Krinsky (34:33):Yeah.Michael Jamin (34:34):So what now I know you also, oh, I wanna mention your, your book. Is it you, you and John, your partner are of the, like, of all the writing teams I've known, even writers I've known, like you guys are the most entrepreneurial, it seems like you, like, you know, there nothing, there's a, there's a path to do it and then there's always like, well let's figure out how else we can do them. You know, you're always like the hustle doesn't end and it's create, it's always like creating opportunities for yourself.Dave Krinsky (34:59):Yeah, I mean certainly. And John's much, much better at that than, I mean he has a very entrepreneurial spirit and I enjoy it though. I like doing things differently. But he's very innovative in the way he thinks he's been in Europe for since, for Covid and for a lot of that. Mm-Hmm. just, you know, kicking the tires in the international market and making some headway there. But like, I remember like a couple of years ago we hooked up and were producing this writer who had done a academy award, docu a nominated documentary, and he had a half hour sitcom and he was he was crypt camp, so he was in a wheelchair and it was a character was about his story. And it was a really cool story. And Obama's company was attached to it. And it was like, this is a great, I mean it's a great script, great project, you know, and we go to Netflix a Zoom pitch and they literally were like this.(35:47):But as soon as the camera came on, you're like, okay, this isn't gonna be a sale. Mm-Hmm. , I mean, we knew it from the get go. Good lesson is you still pitch your heart out cuz you don't wanna ever have to blame yourself. If they don't buy it, they don't buy it. But so was like, what, you know, it's a great pro. Everything was great about it, but you don't know what they want and you just have so little control. So as we say, like shopping around town with our briefcase full of wears like Willie Loman is just not an appealing thing. So, you know, John had met this, this Irish actor, a guy named Richie Stevens, and he was pitching a friend's story and you know, that story wasn't quite hooking John. And then Richie started telling him about his own life and he was a recovered alcoholic drug addict gangster.(36:29):Right. And he is like, oh, that's interesting me, I want you to meet Dave. So we all sat down together, I'm like, I just had a fascinating life, a fascinating story. Like that's a great story to tell. Right. And and it was John's idea too. He was like, rich, you did the 12 steps of, you know, recovery. And he goes, yeah. He goes, let's tell your story in 12 steps. And that lends itself to a very nice TV show. Mm-Hmm. . But we were like, do we really want to go pitch a TV show? And so we said, you know what if we could write this as a book, cuz it lends itself to a book really. Well, 12 chapters. The 12 steps. Right. And I always wanted to write a book from the time I was 12, you know but then we'd have an IP and Hollywood loves an ip, you know, they love it If it's a,Michael Jamin (37:12):You still had to pitch it as a book. I mean you still have to pitch cuz you had to pitch it as aDave Krinsky (37:15):Book. Yeah. It's not like that's an easy path either. Yeah. But look, we had been out here long enough, we knew, you know, Jake Steinfeld Body by Jake who had published several successful books. He goes, well let me introduce you to my book agent. She publishes a lot of nonfiction authors. We'd pitched to her, she said, okay, this is a good hook. I think I can sell it. She turned around and sold it to a publisher. So then, you know, then we wrote the book, which took a while, but it's like now we have a book, which is an ip, which we can set up and we have much more control over it. Yeah. And we're making very good headway and setting it up as a TV show now.Michael Jamin (37:48):Right. Cuz you're bringing, you're bringing more to the table, which is why I always say, what else can you bring to the table? Yeah, yeah, yeah. And I, yeah, and it's an interesting read. I Yeah. Read it. Wonderful. So yeah, I give give you guys a lot of credit, a lot of credit, a lot of hustle.Dave Krinsky (38:03):Well look, a lot of it comes from boredom. And, and in all honesty, there's certain things we can do because of our track record. So when I'm advising like younger writers, I'm like, well, this won't necessarily work for you. Right. But you really do. I mean, the business has become so consolidated. It's a, it's a weird, it's also a weird business where like almost the quality or success of the entertainment doesn't matter. I mean, Apple's trying to sell mm-hmm. , you know, iPhones, Amazon's trying to sell everything else in the world so it doesn't have the same sort of metric as it used to when you were pitching a show. So it, it, it's difficult. But you know, like I met this young writer and she wrote a script that I really liked a lot mm-hmm. and, you know, we tried to set it up around town and have a ton of luck.(38:44):And then we learned she has dual citizenship, I guess triple citizen from Belgium and from France mm-hmm. . And it's like, oh, an American writer who's got, you know, some talent who can go over to the EU and tap into the money over there with their subsidies because she has a, is a huge thing. So now we're making headway on that. Right. So there's a lot of different angles that anybody's starting out might have access to that they can do instead of really just waiting for an agent or a writer or a studio to notice them.Michael Jamin (39:14):Right, right. Stop begging, stop begging, start making, making things happen yourself. Yeah. Yeah. I think so. Well tell, well tell us tell me what the name of that, that book so they can find it on Amazon.Dave Krinsky (39:25):It's called The Gangster's Guide to Sobriety.Michael Jamin (39:27):Yeah. He's a charming fella.Dave Krinsky (39:29):That guy. Yeah. You know, he's a real Irishman with the Irish accent and like, if you read the book, I mean, he did some horrible things and he's always like shocked that people are nice to him cuz of the horrible things he's done. But he's also a very gentle, sweet guy. He was just an, he was an addict and, and he made a lot of bad decisions from there, butMichael Jamin (39:45):Right. Dave Krinsky (39:46):But yeah, he is a good guy. He'sMichael Jamin (39:47):A good story. Yeah. A lot of good stories. Dave Krinsky, I'd give you a hug ifDave Krinsky (39:52):You I wantMichael Jamin (39:53):One , if you weren't on Zoom. Thank you so much. Thank you. Is there anything, any other parting words that we can get from you or anything, any other wisdom? Is that, or we tap, tap you out?Dave Krinsky (40:03):I don't know about wisdom, but I know that you know, a lot of people are, are tuning into you and checking your stuff out. And I just remember at King of the Hill and we've worked together on a bunch of shows, like you were always the fastest guy in the room. I was always just so amazed and, and jokes never translate. And it was your joke, so you'll sound like an idiot. But I just still remember we're all sitting in the writer's room and someone comes in and says, oh, I was down in Century City and I saw that Bewitched movie with will Ferrell and a Nicole Kidman. Yeah. And they go, how was he goes, well, I didn't really get to see it all because there was a fire alarm in the fire department came, came in and you yell everybody out, there's a bomb on the screen.Michael Jamin (40:38):, I don't remember that at, I have no memory of that at all. . My other, myDave Krinsky (40:44):Other favorite memory of King of the Hill was, you remember sitting in that back chair mm-hmm. taking a hole.Michael Jamin (40:50):Yes. And I have, I found a picture of it that was, I'll explain for the, for the, for our viewers we had, right. So there was a while on King of the Hill when we were working like 20 hours a day , and I felt like a hostage. And I had this one big chair that had big wooden legs on it. And I took like a thumb tack and I started digging a hole like the Shawshank Redemption. Redemption. Like I was digging a hole out of the . And then, and it took, it took months to finally when I finally broke through, I put a picture of Rita Hayworth on it so you couldn't see him as digging . And this is ballsy for a new guy. Cause I was like, you know, I was destroying furniture and I was telling everyone that I was not happy to be there 20 hours a day.Dave Krinsky (41:33):. Well, the thing we all, we all kind of bought into this fantasy that when you broke through we'd be free. Right. And it was so depressing when you broke through and we were like,Michael Jamin (41:43):We're allDave Krinsky (41:43):Back to work.Michael Jamin (41:45):I, I remember Garland was particularly interested in it. She's like, well, you know, because she was like, what are you gonna get through? Oh, funny. That's so funny. I'm, I'm glad you reminded that cuz I forget everything. That's the va the advantage of working with people if they can remind me of these stories. I don't remember any of that. I don't remember that that be whichDave Krinsky (42:04): Yeah. No, it was very funny. But no, I this was a pleasure and I I love what you're doing and I think, you know, you're giving information to people that's kind of hard to get anywhere else. You can learn craft, you can learn certain things, but you have so much input that's useful on a day-to-day level for aspiring writers. So good on you.Michael Jamin (42:20):Thank you so much Dave Krinsky, thank you again. AndDave Krinsky (42:24):Pleasure to see youMichael Jamin (42:25):Everyone. So yeah stay tuned. We had more episodes coming up next week. Thanks. And yeah, we have what else we got? We got a free webinar once a month. Sign up for that on my website, michaeljamin.com and my free newsletter. All good stuff. Go to michaeljamin.com and you can find it. Alright everyone, thank you so much.Phil Hudson (42:44):This has been an episode of Screenwriters. Need to Hear This with Michael Jamin and Phil Hudson. If you'd like to support this podcast, please consider subscribing, leaving your review and sharing this podcast with someone who needs to hear today's cycle. For free daily screenwriting tips, follow Michael on Instagram, Facebook and TikTok @MichaelJaminWriter. You can follow me on Instagram, Facebook, and TikTok at @PhilAHudson This episode was produced by Phil Hudson and edited by Dallas Crane. Until max time, keep writing.

How did we achieve nuclear fusion? Neil deGrasse Tyson and comedian Chuck Nice learn about thermonuclear fusion, the world's most powerful lasers, and harnessing nuclear power with operations manager at The National Ignition Facility, Bruno Van Wonterghem.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free.Thanks to our Patrons Gavin Mallow, Willest74, Isaac Labbe, Allen, and Beefcake for supporting us this week.Photo Credit: U.S. Department of Energy from United States, Public domain, via Wikimedia Commons